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Acute Lung Injury, characterised clinically as the Acute Respiratory Distress 
Syndrome is a catastrophic response to a range of pulmonary and non-pulmonary 
insults. Despite much work the key mechanisms involved in generating the 
exaggerated immune response that results in lung injury are not completely 
understood. 
Hypoxia-inducible factor-1 has been shown to be a key transcription factor in the 
myeloid cell response to inflammatory signals. 
The aims of this thesis were to develop a model of acute lung injury and to study the 
role of Hif-1 in the generation of lung injury in this model.  
A model of direct pulmonary injury as a result of intratracheal instillation of 
endotoxin is described. Using this model the role of myeloid cell Hif-1α was 
characterised using a myeloid cell specific conditional knockout system. 
The injury in Hif-1α deficient mice was quantitatively similar to the injury seen in 
wild type animals over a range of time points. However, the quality of the injury, 
assessed by a measure of nitric oxide mediated damage was reduced. 
The in vivo data were supported by in vitro studies using a murine macrophage cell 
line which showed that manipulation of the cellular oxygen tension in the presence of 
endotoxin alters the ability of the cell to generate nitric oxide. Furthermore, 
pharmacological manipulation of cellular Hif-1 levels by Dimethyloxallyl Glycine 
(DMOG) in the macrophage cell increased the generation of nitric oxide in response 
to endotoxin by altering the expression of a number of the isoforms of Nitric Oxide 
Synthase. 
In a final set of experiments the response to intratracheal endotoxin was modulated in 
mice by the concurrent administration of DMOG. As expected the qualitative 
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response to endotoxin was similar but the NO mediated damage was enhanced in the 
animals administered DMOG.  
Manipulation of Hif-1 may have a role in the therapy of lung injury by altering the 
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1.1 Acute Lung Injury and the Acute Respiratory Distress 
Syndrome 
1.1.1 Definitions 
Multiple organ failure (MOF) is the leading cause of death in Intensive Care Units. 
The Acute Respiratory Distress Syndrome (ARDS), first described by Ashbaugh et al 
[1] in 1967 is the pulmonary, and often first, manifestation of this systemic 
inflammatory response. The body responds to a diverse range of insults in a 
stereotyped manner clinically recognisable as the Systemic Inflammatory Response 
Syndrome[2]. This constellation of findings: Body temperature greater than 38C or 
less than 36C; heart rate greater than 90 beats per minute; tachypnoea (respiratory rate 
greater than 20 breaths per minute or PaCO2 less than 32mmHg) and a white cell 
count greater than 12x10
6
 cells/ml or less than 4x10
6
 cells/ml, represents the clinical 
features of a systemic inflammatory process[2]. 
The study of ARDS was initially hampered by a lack of agreement on the clinical 
features of the disease and this resulted in confusion and inconsistency for both 
clinical care and scientific investigation. An American and European Consensus 
Conference (AECC) in 1992 attempted to resolve this confusion by establishing a 
clinical definition of ARDS consisting of 4 criteria: 1. acute onset of disease; 2. ratio 
of PaO2 to FiO2 of less than 200 (regardless of level of positive end-expiratory 
pressure); 3. bilateral infiltrates on a frontal chest radiograph (figure 1-1); and 4. 
pulmonary artery wedge pressure of less than 18mmHg or no clinical evidence of left 
atrial hypertension[3]. The term Acute Lung Injury was also introduced comprising 
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patients exhibiting the above signs but with a PaO2:FiO2 of less than 300. As the 
pulmonary manifestation of SIRS the onset of ARDS is often the event precipitating 
admission to intensive care and heralds the development of the Multiple Organ 




Figure 1-1 Chest Radiograph of patient with ARDS showing bilateral alveolar infiltrates 
 
The AECC definition has been found to be useful both in clinical practice allowing 
physicians to identify the process with easily available data and in clinical studies 
giving an identifiable patient group in whom to apply novel therapies. However, it 
must be appreciated that the AECC criteria are imperfect. When clinical and autopsy 
diagnoses are compared it has been found that the AECC criteria have only a 
moderate  ability to identify both cases and non-cases (sensitivity 75%, specificity 
84%[4]). Furthermore, there is only limited agreement between alternative diagnostic 
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criteria (lung injury severity score [5] and a Delphi definition [6]) [7]. It is also only 
recently being appreciated that different precipitating insults may result in differing 
clinical presentations [8;9] suggesting that future work may need to divide patients 
according to the suspected primary insult (although this may be complicated in the 
critically ill patient who has a degree of sepsis, may have aspirated as a result of a 
reduced level of consciousness and has received blood products as part of goal-
directed therapy[10]).  Despite these limitations however, the AECC criteria have 
allowed the identification of a group of patients who, whatever the exact underlying 
pathology, benefit from a specific ventilatory targets[11] (see section 1.1.5 Therapy of 
ALI/ARDS). Also, the criteria recognise that the severity of lung injury varies (ALI 
versus ARDS) and this may facilitate earlier identification of patients and earlier 
application of interventions to prevent deterioration. 
 
1.1.2 Epidemiology and physiology of ALI/ARDS 
ALI can be the result of direct (most common) or indirect insults to the pulmonary 
system. (Table1-1). The most common direct injury is pulmonary sepsis and the most 
common indirect insult is sepsis. The incidence is variably reported depending on the 
intensive care unit setting and patient population but an incidence of 20-50 per 
100000 person years is widely accepted[12]. The mortality is approximately 40-50% 
but ranges from 30-74% again depending on case mix[12]. Most deaths do not occur 
as a result of respiratory failure (less than 20% of deaths) but rather as a result of 
MODS reflecting the systemic nature of the pathological process. The primary 
physiological problem in ALI is severe hypoxaemia associated with a marked increase 
in minute ventilation as a result of a sharp increase in pulmonary deadspace [13]. 
There is also a decrease in lung compliance with an associated increase in the work of 
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breathing. This combination of factors results in refractory respiratory failure usually 
necessitating intubation and positive pressure ventilation with high fractions of 
inspired oxygen to achieve arterial oxygenation approaching satisfactory levels. 
Table 1-1 Causes of Acute Lung Injury 













Disseminated intravascular coagulation 
Burns 
Neurogenic Pulmonary Oedema 








1.1.3 Pathology of ALI/ARDS 
The histological hallmark of ARDS is Diffuse Alveolar Damage (DAD) [14;15]. 
DAD is characterised by a sequential series of pathological change that occur 
following the injurious stimulus[16]. DAD is the result of severe damage to the 
alveolar-capillary unit[17].  
There are 3 recognised histological phases: Early, exudative phase; proliferative phase 
and fibrotic phase. These phases often overlap and can co-exist in different parts of 
the same patient’s lung. The phases are not necessarily progressive as injury can stop 
and recovery occur at any time.  
Exudative phase 
This phase occurs in the first week following injury and is an acute inflammatory 
response accompanied by a marked influx of neutrophils resulting in injury to the 
alveolar epithelium and vascular endothelium[17]. At necroscopy the lungs are heavy, 
rigid and dark. Microscopically there is extensive alveolar and interstitial oedema 
with hyaline membranes containing immunoglobulin and complement. The 
microvascular and alveolar barriers are damaged with necrosis of alveolar cells. The 
necrosis of type I epithelial cells results in a breakdown of the gas exchange and 
barrier function of the lung which results in flooding of the air spaces with protein 
rich oedema fluid. Endothelial cells swell leading to widening of cellular junctions 
and disrupted barrier function [16]. There is an intense predominantly neutrophilic 
infiltration which is initially seen in the interstitium but extends to involve the 
airspaces[15]. BAL samples show an expanded alveolar neutrophil population [18]. 
Electron microscopy studies show endothelial injury (cell swelling, widened 
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intercellular junctions and increased pinocytotic vesicles) with damage to type I and II 
epithelial cells [19]. The components of the hyaline membranes are mainly derived 
from damaged epithelium, their secretory products and some serum proteins. The 
proliferative phase begins from approximately day 3 onwards. 
Proliferative Phase 
This second stage of DAD is characterised by type II alveolar epithelial cell 
hyperplasia and proliferation with relining of the denuded basement membrane. There 
is an ingrowth of mesenchymal cells and the formation of intra-alveolar organised 
granulation tissue [16]. Type II pneumocytes migrate over the surface of the 
granulation tissue transforming the intra-alveolar exudates into interstitial tissue. 
Called fibrosis by accretion, this is the most important mechanism of remodelling in 
DAD[16]. The end result is of fewer but larger alveoli with more dilated alveolar 
ducts [19]. Macroscopically the lungs are now densely consolidated with re-brown or 
yellow-grey discolouration.  
Fibrotic phase 
Fibrosis can begin within 36 hours of injury but the peak of this phase is seen after 3 
to 4 weeks. There is thickening of the alveolar septa due to collagen deposition with 
few fibroblasts. There are also vascular lesions with mural fibrosis and thickening of 
small muscular arteries, veins and lymphatics. Macroscopically there is extensive lung 
remodelling with alternating areas of microcysts and irregular scarring. However, not 
all patients develop fibrosis [15] for reasons that are not understood. Indeed, if the 
patient survives the event the long term sequelae tend to reflect the neurological 




1.1.4 Pathogenesis of ALI/ARDS 
The pathogenesis of ALI/ARDS is incompletely understood despite much 
investigation[15]. A recent consensus conference on behalf of the National Heart, 
Lung and Blood Institute in the United States emphasised the significant lack of 
knowledge and understanding of the pathological processes seen in these critically ill 
patients [13]. A recent review[21] has summarised the current understanding of the 
interplay between alveolar macrophages (acting as sensing and directing cells), 





Figure 1-2 Summary of cellular interactions during the acute phase of lung injury.  
In the acute phase of the syndrome (right-hand side), there is sloughing of both the 
bronchial and alveolar epithelial cells, with the formation of protein-rich hyaline 
membranes on the denuded basement membrane. Neutrophils are shown adhering to 
the injured capillary endothelium and marginating through the interstitium into the air 
space, which is filled with protein-rich oedema fluid. In the air space, an alveolar 
macrophage is secreting cytokines, interleukin-1, 6, 8, and 10, (IL-1, 6, 8, and 10) and 
tumour necrosis factor α (TNF-α), which act locally to stimulate chemotaxis and activate 
neutrophils. Macrophages also secrete other cytokines, including interleukin-1, 6, and 
10. Interleukin-1 can also stimulate the production of extracellular matrix by 
fibroblasts. Neutrophils can release oxidants, proteases, leukotrienes, and other 
proinflammatory molecules, such as platelet-activating factor (PAF). A number of anti-
inflammatory mediators are also present in the alveolar milieu, including interleukin-1–
receptor antagonist, soluble tumour necrosis factor receptor, autoantibodies against 
interleukin-8, and cytokines such as interleukin-10 and 11 (not shown). The influx of 
protein-rich oedema fluid into the alveolus has led to the inactivation of surfactant. MIF 
denotes macrophage inhibitory factor. Modified from ref [21] 
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As a result of one or often several insults (the so called two hit hypothesis where the 
first insult primes the body to initiate an exaggerated disproportional response to a 
second event) an uncontrolled inflammatory response is generated which results in 
neutrophil recruitment and the generation of alveolar-capillary damage. 
There has been much effort expended in trying to identify a single, key mediator 
responsible for the development of the characteristic features of ARDS. However, it 
would seem increasingly clear that this approach is over simplistic and that the disease 
is the result of a complex interaction of a range of mediators and effector cells which 
may vary between differing clinical precipitants [8;9]. However, a number of 
mediators (see Table 1-2) are consistently identified as being of importance in the 
generation of ARDS. 
 
Table 1-2 Mediators involved in ARDS 
Inflammatory Mediator Function 
TNF-α Pro-inflammatory, Neutrophil activation 
IL-1β Pro-inflammatory, Neutrophil activation 
IL-6 Leukocyte activation, Pyrexia 
Chemokines including IL-8 Leukocyte activation and chemotaxis 
IL-10 Anti-inflammatory 
Platelet activating Factor Leukocyte activation, platelet activation 
Reactive oxygen and nitrogen species Regulation of vascular tone, antimicrobial  
  
  
TNF-α and IL-1β 
Tumour necrosis factor-α and Interleukin-1β are predominantly derived from 
activated macrophages and act via specific receptors. Both are present in the 
bronchoalveolar lavage fluid and plasma of patients at risk of and with ARDS[22] 
with an alveolar-plasma gradient suggesting a pulmonary source. Both are pro-
inflammatory capable of activating inflammatory cells. However anti-TNF-α[23] or 
IL-1β[24] therapeutic strategies have been unsuccessful in clinical trials suggesting 
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that either other mediators have more important roles or that the therapeutic window 
is missed in these trials[25]. 
Chemokines including IL-8 
Chemokines are small cytokines that bind specific G-protein receptors[26]. They 
function in leukocyte trafficking, recruitment and re-circulation. Chemokines are 
present in the BAL of ARDS patients [26]. IL-8 levels correlate with the severity of 
neutrophil infiltration in ARDS. The neutrophil chemotactic activity of ARDS BAL 
has been shown to be predominantly due to IL-8[27;28]. Early neutrophil recruitment 
to lungs mediated by IL-8 may be a key feature in the pathogenesis [29]. 
 
Interleukin-6 
IL-6 is produced by a wide range of cells including monocytes/macrophages, 
endothelial cells and fibroblasts[22]. Circulating levels of IL-6 have been shown to 
predict the severity of ARDS of different aetiologies including pancreatitis[30] and 
sepsis[31].   
Interleukin-10 
IL-10 is an anti-inflammatory cytokine which inhibits the release of pro-inflammatory 
cytokines such as IL-1 and TNF. IL-10 has been shown to inhibit alveolar 
macrophage production of these mediators and clinical studies have found reduced 
levels in patients who had ARDS compared to than those at risk of ARDS[32] but 
without evidence of clinical disease. This emphasises the importance of appreciating 
that it is likely to be the balance between pro- and anti-inflammatory mediators in 
ARDS rather than absolute levels that determines development of disease[25]. 
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Neutrophil products including Elastases and reactive oxygen species 
Neutrophils are effector cells in the development of pulmonary damage in ARDS. The 
uncontrolled release of neutrophil elastase and matrix metalloproteinases by 
neutrophils results in cell injury. Neutrophil elastase compromises the integrity of the 
alveolar-capillary barrier and can cleave exudate proteins such as fibrin into potent 
chemotactic peptides further driving the inflammatory process[33].  
Neutrophils (and alveolar macrophages and epithelial cells) can produce reactive 
oxygen and nitrogen species[22] which have injurious effects on both alveolar 
epithelium and endothelium. Oxidant stress increases endothelial permeability and 
impairs the epithelial transport of sodium ions. Blockage of the synthesis of these 
species has been shown to be protective in a model of ARDS[34]. However, although 
important in the generation of lung injury the neutrophil is not necessary for its 
occurrence. ARDS is recognised to occur in profoundly neutropenic patients 
following bone marrow transplantation[35]. Hence other mechanisms including, but 
not limited to macrophage released mediators, subsequent epithelial and endothelial 
dysfunction, and microvascular thromboses are likely to be of importance [13] in the 
generation of lung injury. 
 
1.1.5 Therapy of ALI/ARDS 
Despite much effort and the insights gained into the pathophysiology occurring, 
therapy for these patients remains suboptimal. The mainstay of therapy is supportive 
care with invasive ventilation, adequate nutrition, renal replacement therapy if 
necessary and treatment of superadded infection. Traditional anti-inflammatory 
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therapy using steroids have shown no survival benefit [36;37]. Other possible 
interventions include inhaled Nitric oxide which, while improving oxygenation 
acutely, does not improve survival [38;39]. In addition prone positioning [40] and 
surfactant replacement [41-43] have proven ineffective. Potential biological therapies 
such as TNFα manipulation are complicated by the difficulties in reconciling an initial 
injurious effect of TNFα with a later reparative effect seen experimentally where both 
anti-TNFα therapy and TNFα administration have resulted in improved 
outcomes[44;45]. 
Currently the only intervention known to improve outcome is a lung protective 
ventilation strategy using a low tidal volume (less than 7ml/kg body weight as 
opposed to the traditional 10-15ml/kg)[11]. A recent Cochrane review has confirmed 
that this approach improves 28 day mortality[46]).  
Therefore there is a need for an improved understanding of both the cellular and 
molecular events to help identify new therapeutic strategies. 
 
1.1.6 Previous work leading to this study 
An important early observation in the study of ARDS was that the BAL level of key 
cytokines (IL-8) was increased in trauma patients at risk of developing ARDS before 
radiological evidence was apparent [29]. This suggested that the critical insults 
occurred before the development of clinically detectable disease and that the 
pathological cellular activation and signalling must also occur early. The search for a 
possible universal initiating insult has been hampered by the diverse range of 
conditions that can result in ALI/ARDS. Furthermore, identification of the timing and 
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sometimes indeed, the exact nature of the insult that leads to ARDS can be difficult in 
many patient groups.  
However, trauma patients generally have a recognised time and mechanism of insult.  
In clinical series of trauma patients hypoxia and hypotension are commonly seen [47]. 
Measures of the severity of global tissue hypoxia (magnitude and duration) in these 
patients predict the development of ALI and MODS [48;49].  Surgical patients present 
a group at risk of ALI in whom the nature of the insult is stereotyped and the timing 
and severity of physiological derangement are known. A group of surgical patients 
particularly at risk of developing ALI/ARDS are those undergoing thoracotomy. It has 
been estimated that about 5% of lobectomy/pneumonectomy patients develop 
ALI[50], termed postoperative lung injury (or postpneumonectomy pulmonary 
oedema in the USA)[51]. Similarly to ARDS in other groups the mortality associated 
with this injury is high (50-100%[51]). It has been recognised at autopsy that the 
pathological changes in the lungs are identical to those seen in ARDS of other 
causes[52]. Thoracotomy requires collapse and re-expansion of the operative lung to 
allow hilar dissection and pulmonary resection. Hence in addition to damage 
sustained during surgical manipulation, the operative lung is exposed to a period of 
hypoxia while the lung is collapsed followed by mechanical distension and hyperoxia 
when ventilatory recruitment manoeuvres are used to re-expand it. The non-operative 
side is also exposed to hyperoxia and, using traditional ventilatory patterns, 
mechanical distension during the period of one-lung ventilation. All of these factors 
singly or in combination could be the trigger for ALI in these patients.  
Further clues to the triggering stimuli can be found in patients who undergo 
oesophagectomy. These patients undergo a thoracotomy in association with 
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abdominal dissection however there is no pulmonary resection and are at high risk of 
ALI/ARDS [53;54]. Oesophagectomy patients have higher serum IL-6 levels post-
operatively compared to patients who have undergone surgery of a similar duration 
limited to the abdomen but with greater blood loss (pancreaticoduodenectomy) 
suggesting that the thoracotomy itself is linked to the severity of the inflammatory 
insult[55]. In these patients perioperative hypoxia is associated with the development 
of ALI [53]. Rocker et al [56] found that the thoracotomy side had a greater increase 
in lung permeability than the non-operative side, suggesting that local pulmonary 
insults are involved in the generation of the systemic changes. Kooguchi et al [57] 
have subsequently shown that there is an increase in BAL cytokines (IL-6 and IL-8) 
in these patients and that the alveolar macrophage is the main source of these. 
Furthermore subsequent analysis of Donnelly’s original data [58] suggested that 
cytokine liberation was correlated with the severity of hypoxia. Kooguchi et al [57] 
have also shown that the intensity of macrophage cytokine expression correlates with 
measures of hypoxia. 
Re-expansion pulmonary oedema is a potentially fatal condition that can be seen after 
rapid re-expansion of a collapsed lung as a result of treating a pneumothorax or 
pleural effusion. The collapsed lung, following a period of hypoxia, is rapidly 
reexpanded and the alveoli are exposed to inspired oxygen. Nakamura et al [59] have 
shown in a rabbit model that alveolar macrophages in the hypoxic lung secrete IL-8 
before re-expansion and that treatment with a monoclonal anti-IL-8 antibody reduces 
the severity of the lung injury again linking alveolar hypoxia to lung injury mediators. 
Finally, high altitude pulmonary oedema occurs in mountaineers who are exposed to 
alveolar hypoxia as a result of the decrease in partial pressure of oxygen at high 
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altitudes. Studies have shown that these patients have increased BAL inflammatory 
cells[60] and cytokines (increased IL-1β,-6,-8 and TNFα) [61], although these are not 
universally found [62]. 
Using both animal models and in vitro studies the potential pro-inflammatory nature 
of hypoxia has been recognised.  Ertel et al [63] showed that in mice exposed to 
hypobaric hypoxia the plasma TNF-α and IL-6 were elevated and that peritoneal 
macrophages isolated from hypoxia exposed animals produced greater quantities of 
TNF-α, IL-1 and IL-6 in response to endotoxin stimulation in vitro. Metinko et al[64] 
have shown that human monocytes exposed to anoxia/reoxygenation secrete IL-8 and 
that in response to endotoxin the response is further exaggerated. In rats normobaric 
hypoxia alone has been found to induce pulmonary inflammation in the absence of 
any other insult [65] with features similar to ALI. Furthermore hypoxia has been 
shown to affect neutrophil function delaying apoptosis [66] and enhancing cytotoxic 
function [67]. Therefore, an early event such as pulmonary regional hypoxia which 
occurs before the development of ALI (as a result of pulmonary contusion in trauma, 
consolidation in pneumonia or atelectasis in critically ill patients) is a potential 
stimulus for the development of lung injury.  
Other stimuli such as hyperoxia [68] and mechanical stretch during mechanical 
ventilation [69;70], both of which are used to treat ARDS, can undoubtedly contribute 
to the development of ALI/ARDS. However, in the search for a common early insult 
which occurs before the onset of clinical disease hypoxia seems to be an area of great 
potential. 
Results of the work described above suggest that the alveolar macrophage may be a 
key target for the injurious stimulus that initiates ALI/ARDS. The lung is composed 
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of a number of different resident cell populations (including Type I and Type II 
alveolar epithelium, pulmonary endothelium and macrophages) which could singly, or 
in concert, trigger the cascade of inflammatory mediators that results in ALI/ARDS. 
However, the alveolar macrophage occupies a prime position to sense injurious 
stimuli at the air/fluid interface [71] and is able to respond to such stimuli by secreting 
a number of mediators which could trigger an inflammatory response (see table 1-2).  
Although well recognised that there is a massive pulmonary neutrophil influx in 
ARDS, it is less recognised that in both humans [72]  and animal models [73;74], 
there is also an expansion of the macrophage pool. Furthermore, in humans there is 
evidence of activation of alveolar macrophages (specifically activation of 










o Tumour Necrosis Factor 
o Interferon-α/γ 
o Colony stimulating Factors 
o Transforming Growth factor-β 
o Fibroblast Growth factor 
o Platelet Derived Growth Factor 
o Vascular Endothelial Growth Factor 
 Enzymes 
o Lysosyme 
o Acid hylauronidases 
o Angiotensin Converting Enzyme 
o Elastases 
o Collagenases 
o Plasminogen activator 
 Biologically active lipids 
o Cycloxygenase metabolites- Thromboxane A2, Prostaglandins 
 Oxygen metabolites 
o Hydrogen Peroxide, Superoxide, Hydroxyl radical 
o Nitric oxide 
 Proteins 
o Antiproteases- plasminogen activator inhibitor-1 
o Complement components-C2, C4 
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In animal models of ALI, activation of the NF-κB transcription pathway in alveolar 
macrophages occurs before pulmonary damage[76] and depletion of the alveolar 
macrophage population results in striking attenuation of lung injury in a number of 
models[76-78]. To further support the importance of the alveolar macrophage it has 
been shown by adoptive transfer experiments that BAL cells from rats exposed to 
intratracheal LPS can induce ALI in naïve animals[79]. While some of this damage is 
undoubtedly due to transfer of neutrophils it is recognised that ARDS can occur in 
neutropenic patients[80] and that the resting non-inflamed lung has no resident 
alveolar neutrophils [71] suggesting that, while the neutrophil is the major effector 
cell in ALI [81], another cell is responsible for detecting and responding to the initial 
stimulus. Hypoxia has been shown to trigger the release of key mediators in 
ALI/ARDS such as IL-8 and TNFα [82;83] by alveolar macrophages.  
The alveolar macrophage is also able to respond to other injurious stimuli which are 
seen in patients with ALI including hyperoxia [82;84-86], mechanical stretch[87] and 
haemorrhagic shock and sepsis [88]. 
 The possible importance of the hypoxic sensing and control of the inflammatory 
response in ALI/ARDS was further enhanced by the identification of a novel key 
transcription factor Hypoxia inducible factor-1 (Hif-1) which seemed to play a key 
role in the development of inflammation [89].  
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1.2 Hypoxia inducible factor-1  
 
1.2.1 Identification and description of Hypoxia inducible factor-1 
The gene coding for the hormone erythropoietin (EPO) was cloned in 1985[90] and it 
was subsequently shown that EPO levels increase in response to hypoxia[91]. 
Furthermore this signal was not detected by the electron transport chain as cyanide did 
not reproduce the effect. Gregg Semenza’s laboratory subsequently identified the 
transcription factor, Hypoxia-inducible factor 1 (Hif-1) as the key mediator of the 
transcriptional response to cellular hypoxia[92]. 
Hif-1 is a heterodimer  composed of an α and β subunit (Figure 1-3)[92]. The 789 
amino acid β subunit is constitutively expressed in all cells and is also known as aryl 
hydrocarbon nuclear receptor translocator (ARNT) [93]. Human Hif-1α is an 826 
amino acid protein which is constitutively expressed in all nucleated cells. It is a 
member of the basic-helix-loop-helix (bHLH) PAS (Per-Arnt-Sim) family of 
transcription factors. The Human Hif-1α gene, HIF-1A, is encoded on chromosome 14 
(14q21-24) [94] and continuous transcription is initiated by Sp1 binding sites in the 5’ 
region. The murine hif-1a gene is encoded on chromosome 12 [94] and shares a 90% 
amino acid identity with the human equivalent. 
Hif-1β is also a member of the bHLH PAS family and both Hif-1α and -1β contain 2 
PAS domains (PAS A and B) in the amino terminal of the proteins. These 100-120 
amino acid long domains form 5 stranded anti-parallel β sheets which are flanked by 
several α helices [95] and mediate heterodimer formation and DNA binding [96]. 
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The remainder of the Hif-1α protein has also been characterised and has been shown 
to be composed of a number of subunits that are critical to its oxygen sensitive 
regulatory role. The COOH terminal of Hif-1α contains 2 transactivation domains, 
one NH2-terminal transactivation domain, (N-TAD), located at amino acids 531-575 
and the other, COOH-terminal (C-TAD), which are essential for the transactivation 
activity of Hif-1. These 2 regions show 100% homology between mouse and human 
Hif-1α [97]. Between these two regions is the Inhibitory Domain (amino acids 576-
785) and this has a 75% homology between human and mouse. Both N-TAD and C-
TAD are able to initiate transcription of Hif-1 target genes however C-TAD also 
requires the binding of CBP/p300 for activity. There are two nuclear localisation 
signals which are localised to the amino terminal (amino acids 17-74) and carboxy 
terminal (amino acids 718-721) [96].  The region between amino acids 401 and 603 
(i.e. overlapping with N-TAD but separate to C-TAD) is the Oxygen Dependent 
Degradation (ODD) domain [98] responsible for the unique oxygen mediated 
regulation of Hif-1.  
The human HIF-1A gene has been characterised and is composed of 15 exons and 14 
introns. Exon 2 codes for the bHLH sequence, exons 3-8 code for the 2 PAS domains 
while 9-15 code for the TAD/ODD domains. A number of isoforms of Hif-1α have 
been identified (see Lee et al [99]) but their exact functions remain uncertain. There 
are two other members of the bHLH-PAS superfamily Hif-2 and Hif-3. Hif-2 shares 
the same β subunit as Hif-1α. Hif-2α is also known as endothelial PAS [EPAS] 
protein, HIF-related factor [HRF], HIF-like factor [HLF] and member of the PAS 
superfamily 2 [MOP2][100]. Hif-2α shares a 48% homology with Hif-1α [94]. The 
expression of Hif-2 is more limited [101;102]. The differential roles for Hif-1 and 
Hif-2 are unclear. Hif-1α and 2α are not functionally redundant as knockout of either 
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is embryonically lethal. Hif-1α knockout mice die by day 11 [94;103] as a result of 
lack of blood vessel formation and neural fold defects. All glycolytic enzymes are 
Hif-1 regulated  [104] while some genes are targets for both Hif-1 and-2 (e.g. 
Vascular Endothelial Growth Factor) . Hif-3α does not have a TAD and may be a 
negative regulator of hypoxic responses [105-107].  
 
Figure 1-3 Structure of Hypoxia inducible factor-α 
 
1.2.2 Hif-1 mechanism of action and target genes 
Transcription factors are endogenous substances (usually a protein) that are effective 
in the stimulation /initiation of the genetic transcription process. Both Hif-1α and -1β 
are constitutively expressed in the cytoplasm. Following nuclear translocation and 
dimerisation they bind to target gene DNA via the Hypoxia Response Element (HRE; 
5’-RCGTG-3’) and initiate transcription. For full activity Hif-1α must bind CBP 
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(CREB binding protein)/p300 at the C-TAD [108]. This occurs via the 
Cysteine/Histidine-rich 1 (CH-1) domain of CBP/p300. The binding of CBP/p300 has 
2 functions. First it acts as a link between the DNA binding protein and the 
transcription initiation complex containing RNA polymerase II. CBP/p300 also has 
histone acetyltransferase activity which allows chromatin remodelling required for 
transcription [109]. 
1-2% of human genes are regulated by hypoxia [110]. There are now over 70 genes 
that have been identified as Hif-1 regulated (Table 1-3). The central role of Hif-1 is to 
promote the cell’s adaptation to hypoxia. This is done by increasing the cell’s ability 
to synthesis ATP from glucose by glycolysis by increasing the enzymes controlling 
glucose uptake (GLUT-1) and glycolysis (LDH-A) [95]. Other target genes increase 
the delivery of oxygen to cells (EPO, transferrrin, VEGF). 
The key control of Hif-1 function, both transcription initiation and termination of 




Table 1-4 Hif-1 Regulated Genes 
 
 Energy metabolism   






o Phosphoglycerate kinase-1 
o Lactate dehydrogenase-A 
 Hormonal regulation 
o Erythropoietin 
o Leptin 
 Angiogenetic signalling 
o Vascular endothelial growth factor-A 
o Endothelial-gland-derived vascular 
endothelial-growth factor 
o VEGF Receptor-1 (Flt-1) 
o Plasminogen activator inhibitor-1 
 Vasomotor regulation 
o Endothelin-1 
o Adrenomedullin 
o Tyrosine hydroxylase 
o α1-adrenergic receptor 
o Inducible nitric oxide synthase (Type 
II NOS) 
o Haem-oxygenase-1 
o Atrial natriuertic peptide 
o Endoglin 
 
 Growth and apoptosis 
o Insulin-like growth-factor-binding-
protein-1 
o Nip 3 
o Wilms tumour suppressor  
o Calcitonin-receptor-like receptor 




o Transferrin receptor 
o Ceruloplasmin 
o Multidrug-resistance P-glycoprotein 
 Transcriptional regulation 
o CITED2 (p35srj) 
o ETS1 
o Differentiated Embryo-chondrocyte 




o Adenosine A2B receptor 
 Nucleotide metabolism 
o Adenylate kinase 3 
 Ecto-5’-nucleotidase 
 pH regulation 




1.2.3 Regulation of Hif-1α protein levels and activity by oxygen 
 
The control of Hif-1 protein levels and activity is controlled by the cell’s ambient 
oxygen level (summarised in figure 1.4). The control is focussed on the Hif-1α 
subunit. If Hif-1α is over expressed in a cell the activity at reporter HRE increases 
confirming that Hif-1β is present in excess and is not the limiting factor [97]. 
 
Figure 1-4 The oxygen dependent regulation of Hif-1α.  
The oxygen dependent degradation of Hif-1α can be viewed in 4 stages. 
Stage 1: In the presence of oxygen PHDs hydroxylate Proline residues 402 and 564 
Stage 2: FIH-1 can also hydroxylate Aspargine 803 
Stage 3: The hydroxylated Proline residues allows vHL to bind to Hif-1 while the interaction 
between Hif-1 and the transcription cofactors CBP/p300 is inhibited by the Asn hydroxylation 
Stage 4: The binding of the vHL/ubiquitin complex targets Hif for destruction by the 26S 
proteasome complex. 
O2 oxygen; 2-OG 2-oxoglutarate; PHD prolyl hydroxylase; OH hydroxyl group: FIH-1 
Factor Inhibiting Hif-1: VHL von Hippel Lindau protein: Ub Ubiquitin: CBP/p300 CREB 




The half life of de novo synthesised Hif-1α in vitro is about 5 minutes [111]  and is 
dependent on the presence of the ODD [98]. In the presence of oxygen Hif-1α is 
targeted for degradation by the product of the von-Hippel Lindau (pVHL) tumour 
suppressor gene [112;113].  pVHL binding directs the formation of the VCB-Cul2 E3 
ligase composed of elongin C, elongin B, cullin-2 and Rbx1 [114]. This multiprotein 
E3 ligase causes the polyubiquitination of the Hif-1α subunit and targets it for 
degradation via the 26S proteasome pathway [95;111;115]. The key discovery in 
understanding the oxygen regulated control of Hif-1α protein levels was the discovery 
that the mechanism for pVHL recognition of the -1α subunit required the 
hydroxylation of 2 proline residues in the ODD. In the presence of oxygen Pro 402 
and 564 are hydroxylated by a family of enzymes the Prolyl Hyrdoxylases (PHD) 
[116;117]. PHDs belong to the 2-oxoglutarate dioxygenase family which are non-
haem Fe2+ dependent enzymes [118]. There are 3 isoforms (PHD 1-3) which were 
isolated on the basis of their homology to the elg9 hydroxylase enzyme of the 
nematode Caenorhabditis elegans [119]. The major functionally active isoform of 
PHD is PHD2 [120]. The physiological function of the remaining isoforms is unclear. 
To function PHD require the presence of oxygen, Fe2+ and 2-oxoglutarate. The 
proline hydroxylation reaction results in one oxygen atom being transferred to the Pro 
residue while the other reacts with 2-oxoglutarate to form succinate and carbon 
dioxide. Ascorbic acid catalyses the reaction by maintaining iron in the ferrous state 
(Fe2+) [119;121].  
The nature of the oxygen sensor remains an area of debate but a unifying model can 
be conceived which allows the experimental results of differing groups of 
investigators to be reconciled. (The regulation is summarised in Figure 1-3) 
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Conceptually the simplest view is to consider the situation in anoxia. Here in the 
absolute absence of oxygen Hif-1α is stabilised as a result of lack of substrate for the 
PHDs. The measured Km [O2] for recombinant PHD is in the range of 230-250μM 
[122] (the Km [O2] for complex IV of the mitochondrial respiratory chain is <1μM). 
These values are above the physiological (and therefore pathophysiological) levels of 
cellular oxygen and hence these enzymes are acting under non-equilibrium conditions 
and can act as the oxygen sensor. This model suggests that in hypoxia (as opposed to 
anoxia) as oxygen availability decreases (and the majority of that available is 
consumed by the respiratory chain) there is a corresponding decrease in the activity of 
the PHD and hence an increase in cellular Hif-1α levels. 
However there is a dispute that the oxygen sensor is the PHD. It has been shown in 
Hep3B cells that in hypoxia (as opposed to anoxia) that the presence of functioning 
mitochondria is required to allow Hif-1α stabilisation [123]. Rho zero cells 
(mitochondrial deficient cells) while able to stabilise Hif-1α in anoxia are unable to 
stabilise Hif-1α in hypoxia. Equally inhibitors of mitochondrial function are able to 
stop the hypoxia mediated Hif-1α stabilisation. Furthermore in the absence of 
mitochondria the stabilisation of the α subunit by iron chelators is maintained. 
Chandel et al [123] have suggested that the key to understanding the role of the 
mitochondria as the oxygen sensor is to propose that in hypoxia there is increased 
generation of reactive oxygen species (ROS) at complex III of the electron transport 
chain. In the presence of increased ROS there is altered cellular Fenton chemistry 
with an increase in ferric (Fe3+) iron which inhibits the action of the PHDs which 
require ferrous (Fe2+) iron.  
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The two views of the PHD or the mitochondria as the oxygen sensor do not have to 
oppose and it would seem that an increase in the proportion of oxygen being utilised 
by the electron transport chain, reducing the availability of oxygen to the PHDs plus 
an alteration in the redox state of the PHD cofactors together can act as a rapidly 
responsive system to changes in cellular oxygen. 
The activity of stabilised Hif-1α is further regulated by the cellular oxygen level. For 
full activation the C-TAD requires the binding of CBP/p300. This is controlled by the 
activity of another hydroxylase- Factor inhibiting Hif-1 (FIH-1). In the presence of 
oxygen FIH-1 hydroxylates Asn 803 which prevents the interaction with CBP/p300 
[124;125]. Furthermore FIH-1 acts as a repressor of Hif-1α activity by recruiting 
Histone deacetyltransferases resulting in an unfavourable chromatin structure for 
transcription [126]. 
Finally prolonged hypoxia may result in altered Hif-1α transcription. This has recently 
been shown in A549 cells where prolonged (>12 hours) resulted in reduced levels of 
Hif-1α mRNA [101]. This was proposed to occur through an increase in Hif-1α 




1.2.4 Regulation of Hif-1α by non-hypoxic pathways 
 
There has recently been increasing evidence that Hif-1 is also controlled through non-
oxygen mediated pathways, mediated via more classical signalling pathways (see 
figure 1-4). A range of signalling molecules including insulin, platelet derived growth 
factor, epidermal growth factor, fibroblast growth factor-2, TNFα and thrombin (see 
[128] have been shown to increase either Hif-1α mRNA or protein levels. These 
molecules signal via two pathways- the Mitogen Activated Protein Kinase (MAPK) 
and Phosphatidylinositol 3-kinase/Akt (PI3K) pathways. Using Chinese hamster 
fibroblasts (CCL39) Richard et al [129] have shown that Hif-1α is phosphorylated by 
p42/44 and that the phosphorylated Hif-1α has greater transcriptional activity. 
Recently Sang et al [130] have also shown that in the human cervical carcinoma HeLa 
cell line CBP/p300 can be phosphorylated by MAPK and that this increases the 
transcription signal. Also Hif-1β can preferentially bind the phosphorylated form of 
Hif-1α [131] (in a breast carcinoma cell line MCF-7). 
Others have shown that the PI3K pathway can result in increased Hif-1α protein 
levels in normoxia [132-135] (in a range of cells including porcine proximal renal 
tubular LLC-PK1 cells[132]; the human liver carcinoma lineHepG2 [133]; the 
glioblastoma cell line U373 [134] and the mouse embryonic fibroblast cell line 
NIH3T3 [135] (see diagram from Bilton& Booker [128]). These signals generate an 
increase in protein levels which is thought to be enough to overwhelm the PHD 




Other transcription factors also affect Hif-1 dependent pathways. p53 can decrease the 
activity of Hif-1α via several pathways. Blagosklonny et al [136] have shown that p53 
can inhibit CBP/p300 interaction in human carcinoma cell lines (SKBr3, MCF7 
human breast cancer cell lines and PC3M a highly metastatic variant of the prostate 
cancer cell line, PC3) as both p53 and Hif-1α bind to the CH1 rich region. Also in a 
colorectal carcinoma line (HCT116) p53 increases the levels of mdm-2 an alternative 
E3 ubiquitin ligase which can target Hif-1 for proteosomal destruction [137]. 
These discoveries suggest that there exists a range of controlling pathways which are 
















Receptor mediated increase in 
Hif-1 regulated gene activity
 
Figure 1-5 Non-hypoxic regulation of Hif-1α 
Receptor activation leads to signalling cascades via the MAPK and PI3K pathways 
which lead to increased Hif-1α protein synthesis and activity. 
MEK MAPK kinase; MAPK Mitogen Activated Protein Kinase; PI-3K Phosphatidyl 
Inositol 3 kinase; AKT serine/threonine protein kinase Akt ; FRAP FKBP12-rapamycin 
complex-associated protein; p70
S6K
 ribosomal protein S6 kinase, 70kDa, 
polypeptide 1; eIF-4E eukaryotic translation initiation factor 4E   
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1.3 Role of Hif-1 in inflammatory disease. 
Pro-inflammatory signal such as IL-1β and TNFα have been shown in vitro to 
increase Hif-1α mediated signalling [138]. It has also been shown in primary 
inflammatory cells that Hif-1α protein is increased in a model of tissue injury [139]. 
A recent key paper [89] has suggested that Hif-1α may have a central role in 
controlling the myeloid cell mediated inflammatory response. Using a myeloid cell 
conditional knockout mouse (exon 2 targeted and therefore deficient in the bHLH 
sequence [140]) Cramer et al [89] were able to shown reduced myeloid cell function 
both in vitro and in several murine models of inflammatory injury. Kong et al [141] 
have also shown that the migration of inflammatory cells is also regulated in a Hif-1α 
dependent manner. Finally in macrophages Blouin et al  [142] have shown that 
endotoxin, a key possible trigger of ALI, can increase both Hif-1α mRNA and protein 
via the PI3K pathway. 
On the basis of this work this thesis aimed to undertake a study of the role of Hif-1α 




1.4 Aims and hypothesis 
This thesis was undertaken to test the hypothesis that hypoxic and non-hypoxic 
signals via the Hif-1 transcription apparatus controlled the alveolar macrophage 
response to stimuli associated with the development of acute lung injury. 
In order to test this, the aims of this work were to: 
1. Develop a model of acute lung injury in mice. 
2. Study the effect of Hif-1α depletion in the myeloid cells of mice using the 
model. 
3. Study the effects of manipulating Hif-1α in vitro both via hypoxic culture and 
pharmacologically in an alveolar macrophage cell line in response to a well 
recognised inflammatory stimulus (endotoxin). 
4. Determine the feasibility and effects of manipulating Hif-1 in vivo in the 



















2.1 Tissue Culture 
2.1.1 General cell culture 
Media 
 
Unless otherwise specified medium was RPMI 1640 (PAA Laboratories, Yeovil, UK) 
supplemented with10% foetal calf serum (FCS) (GIBCO BRL, Life technologies 
Paisley UK), 2mM L-glutamine (PAA), 50μM β-mercaptoethanol (PAA) and 
100U/ml penicillin and 100μg/ml streptomycin (PAA). 
PBS for cell culture was purchased from PAA. 
 
Plasticware 
All tissue culture flasks and plates were supplied by Corning Life Sciences. 
 
Cell line 
The alveolar macrophage cell line MH-S (ATCC CRL-2019) was derived from 
Simian Virus 40 transformed alveolar macrophages obtained from Balb/cJ mice [143] 
was obtained from the ATCC. They have been shown to have functional similarity to 
primary alveolar macrophages [143;144]. MH-S cells express well characterised 
murine macrophage surface antigens including CD11b, CDw32 (FcγII Receptor), 
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F4/80 and class II MHC. As would be expected they do not express CD4 or CD8. 
MH-S cells secrete IL-1 and nitric oxide in response to endotoxin. 
Cells were cultured at 37
0
C in a 5% CO2 atmosphere routinely. 
Cells were passaged every 2-4 days when subconfluent. After washing excess media 
with PBS cells were incubated for 10 minutes in Trypsin/EDTA (0.5mg/ml and 
0.22mg/ml respectively) solution (PAA) at 37
0
C. The tryspin was then inhibited by 
addition of an equal volume of complete medium and the cell suspension then 
centrifuged at 300xG for 5 minutes. The cell pellet was then resuspended and the cell 
number counted using a haemocytometer. Culture flasks were then seeded at a density 
of 1x10
5
cells/ml in an appropriate volume of complete medium. 
For experiments cells were split as described and then plated into appropriate sized 
tissue culture plates. Generally cells were plated in triplicate for each experimental 
condition. 
 
2.2 Cell assays 
2.2.1 Lactate Dehydrogenase Assay 
As a measure of cell death the release of Lactate Dehydrogenase (LDH) was 
measured in the supernatant in some experiments. This was done using the in vitro 
Toxicology assay TOX-7 (Sigma Aldrich, Dorset, England). To allow calculation of 
percent cell death triplicate wells were treated with the supplied lysis solution which 
reproducibly results in complete death of all the cultured cells.  
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2.2.2 Nitrite assay 
 
The production of Nitric oxide (NO) was measured using the Griess assay which 
measures the level of Nitrite (NO
-
2) in medium, one of the stable breakdown products 
of NO. This was done using the colourimetric Griess Reagent system (Promega 
Corporation, Madison, WI, USA). The sensitivity of the assay is 2.5μM nitrite. 
Assays were performed in 96 well plates and read at 520nM using a plate reader and 
Gen 5 software. 
2.2.3 Enzyme-linked Immunosorbent Assays 
 
Cytokine levels in cell supernatant and bronchoalveolar lavage fluid were measured in 
accordance with manufacturers’ instructions in 96 well plates. Murine TNF-α kits 
were supplied by Insight Biotechnology (Wembley,UK). Murine CXCL 12 and 
murine MIP-2 were measured with kits supplied by R+D (R+D Systems, Abingdon, 
UK). 




Figure 2-1. Standard curve generated using the TNF ELISA. Duplicate wells were run 
using serial dilutions from 1000 to 8pg/ml. 
 
2.2.4 Cytometric Bead array assay 
 
In some experiments cytokines were measured using the BD Cytometric Bead Array 
system (BD Biosciences, Oxford, UK) which allows the simultaneous measurement 
of  6 murine specific cytokines (IL-6; IL-10; IL-12; MCP-1, IFN-γ and TNF) in the 
same sample. Manufacturers’ instructions were followed other than reagent volumes 
were halved in order to increase the number of tests per kit as is standard practice in 




















2.3 Total protein extraction 
To collect total cell protein for western blot analysis cells were cultured in 100mm 
tissue culture treated culture dishes. Following exposure to the experimental 
condition(s) total cell protein was collected as follows. 
Dishes were transferred on ice and the conditioned medium was decanted off and the 
cells were washed twice with ice cold PBS. Cells were then lifted by scrapping in 0.5l 
of cold PBS and pelleted by centrifugation at 6000rpm for 2 minutes at 4
o
C.  Cells 
were then lysed by the addition of an appropriate volume of RIPA buffer (Pierce, 
Thermo Fisher Scientific, Cramlington, UK) containing Halt Protease inhibitor 
cocktail (Pierce). The lysate was then agitated for 15 minutes on ice and then the 
cellular protein was collected by centrifugation at 13000 rpm for 15 minutes at 4
o
C to 





2.4 Nuclear Protein extraction 
In order to perform Western blots to study the levels of Hif-1α it was necessary to 
collect separate nuclear and cytoplasmic fractions of cellular protein. Cells were again 
cultured in 100mm tissue culture treated culture dishes. At the end of the experimental 
period the cells were transported on ice and then quickly washed twice in ice cold 
PBS. Cells were then collected by scrapping and collected in cold PBS. Following 
centrifugation at 6000rpm for 2 minutes at 4
o
C the cell pellet was collected and the 
cells were lysed using NE-PER nuclear and cytoplasmic extraction kit (Pierce). In 
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order to maximise the concentration of nuclear protein obtained the recommended 
volumes of reagents CER I and CER II were used but the volume of NER was halved. 
Protease inhibitor cocktail was added at both the cytoplasmic and nuclear extraction 
steps. The cytoplasmic and nuclear extracts were both stored at -70
o
C until needed. 
 
2.5 Protein Assay 
To quantify the amounts of nuclear, cytoplasmic or total protein obtained by the 
above procedures the protein concentration was measured using the BCA protein 
assay (Pierce) which is not affected by the components of the lysis buffers. 
Manufacturer’s instructions were followed for the microplate procedure which 
depends on the development of a purple colour following the reduction of copper by 
alkaline media and its subsequent chelation by bichinoninic acid. Assays were 
performed in a 96 well plate and read at 562nm by a plate reader and Gen 5 software. 






2.6 Western blot  
2.6.1 General Protocol 
Protein extract was mixed with an appropriate volume of NuPAGE (x10) reducing 
agent and Loading buffer (x4) (Invitrogen) and heated for 10 minutes at 70
 o
C.  
The protein was then resolved on pre-cast Novex Bis-Tris Gels (Invitrogen) by 
electrophoresis at 200V for 35 minutes. Protein was then transferred to PVDF 
(Amersham). Membranes were blocked with 5% milk (Marvel) in Tris buffered saline 
(TBS) for 30 minutes at room temperature. Primary antibody incubation was 
performed overnight at 4
 o
C. The membrane was then washes 3 times in TBS/0.1% 
Tween (TBS-T). A species appropriate polyclonal HRP conjugated antibody was then 
incubated for 1 hour at room temperature. Following three further washes with TBS-T 
signal was detected by chemiluminescence using SuperSignal West Femto (Pierce). 
Images were obtained using a Bio-Rad Versa Doc 4000 imaging system. Images were 
stored on a PC using the supplied Quantity one software. 
 
2.6.2 Antibodies used in Western blots 
Primary antibodies 
The following antibodies were used to detect proteins of interest. 
Hif-1α polyclonal antibody (Cayman Chemicals). A polyclonal rabbit IgG raised 
against the C-terminal amino acids 809-826 of the Hif-1α protein. A final 
concentration of 5ng/ml was used. 
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Hif-1α monoclonal antibody (BD Transduction Laboratories, BD Biosciences, 
Oxford) A monoclonal mouse IgG1 directed against the C-terminal amino acids 610-
727 of the Hif-1α protein. This antibody failed to detect murine Hif-1α by Western 
blot or immunohistochemistry. 
Hif-1α monoclonal antibody (Abcam). A mouse monoclonal IgG2b directed against 
amino acids 432-528 of Human HIF1 alpha. This antibody was able to faintly detect 
murine Hif-1α protein on Western blot (see in vivo chapter). 
nNOS rabbit polyclonal  antibody. (BD Biosciences). This antibody was raised 
against the C-terminal amino acids 1095-1289 of human nNOS. A final concentration 
of 0.5μg/ml was used. 
iNOS Mouse IgG1 monoclonal antibody (BD Transduction Lab). This antibody 
generated against the C terminal amino acids 961-1144 of mouse iNOS was used at a 
final concentration of 0.25ng/ml. 
eNOS rabbit polyclonal antibody (Abcam) This antibody has been raised against 
amino acids 1179-1194 of human eNOS. This was used at a final concentration of 
0.2ng/ml. 
Cre rabbit polyclonal antibody (Novus Biologicals Littleton, CO, USA) This antibody 
was raised against the 35kDa bacteriophage P1 Cre recombinase. It was used at a 
dilution of 1:10000. 
Heme-oxygenase-1 antibody (Stressgen, Ann Arbor, Michigan, USA). Raised against 
native rat liver HO-1 protein this antibody detects a 32kDa protein. It was used at a 




Species appropriate Horse Radish Peroxidase (HRP) labelled antibodies were 
obtained from Dako (Dako Cytomation, CA, USA). These were used at a final 
dilution of 1:10000 as per the instructions in the Supersignal West Femto system. 
 
2.3 Hypoxic and hyperoxic cell culture conditions 
Variable oxygen conditions were achieved in a humidified variable aerobic chamber 
(Oxycycler Model C42, Biospherix Limited, Redfield, New York). This system is 
controlled by a PC running Watview Runtime Version 2.5.63 and rapidly achieves the 
desired ambient oxygen condition by controlling the inflow mixture of oxygen and 
nitrogen. All cell culture was performed in the presence of 5% CO2. The chamber was 
calibrated by the supplier’s engineer using precision generated calibration gas to 
ensure accurate results during regular servicing. 
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2.4 Animal Techniques 
All animals used in this thesis were housed in the Animal Facilities of the Biomedical 
Research Resource Unit of the University of Edinburgh. Initially the facility in the 
Hugh Robson building was used but the animals were moved to the new facility in the 
Chancellor’s Building, Little France. These facilities are specific pathogen free. All 
animals were maintained on a 12 hour day/night cycle and had unrestricted access to 
food and water. 
All procedures were performed in accordance with Home Office Regulations and had 
Local Ethical Committee approval. As the models investigated in this thesis were 
deemed to be severe insults there was frequent oversight by local and Home Office 
veterinary surgeons. 
 
2.4.1 Purchased animals 
FVB male mice were purchased from Harlan (Huntington, England). Mice were 
purchase aged 6-8 weeks and allowed to acclimatise for at least one week before use 
in an experiment. These mice were housed singly to prevent fighting. 
The FVB strain is derived from White Swiss mice [145] and has been found to be 
useful in transgenic research due to the relatively large size of its pronucleus [146]. 
This has lead to its use in a number of studies characterising the response to 
inflammatory insults in the lung [147;148], systemically [149;150] and in other 
organs [151;152]. FVB mice have physiological reactions to insults such as endotoxin 
[149;153] and hypoxia [154] similar to those seen in humans. Furthermore, FVB 
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strongly express CD14 on macrophages but much less intensely on other tissues [149] 
and as this thesis is concerned with the macrophage response to insults this may be a 
benefit. 
 
2.4.2 On-site bred animals 
The Myeloid cell specific knockout animals used in this thesis were a kind gift from 
Professor R. Johnson of the University of California, San Diego, USA. They were 
rederived by the staff of the BRR facility and bred in a pathogen free environment. 
Genotyping was performed from ear clips obtained by the BRR staff. Animals were 
designated as Cre negative (i.e. wild type) or positive (i.e. knockout) by real time PCR 
using in house designed probes by the BRR facility. In experiments, where possible, 
cre positive and negative litter mates were used. 
 
2.4.3 General Anaesthesia 
In this thesis two methods of inducing general anaesthesia were used.  
Initially animals were anaesthetised by inhalation of the volatile anaesthetic 
Isoflurane. This was done using oxygen as the carrier gas and results in the rapid 
induction of surgical anaesthesia. This technique results in the rapid recovery of the 
animals once removed from the volatile agent and this technique was used during the 
haemorrhagic shock model. 
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The other method of anaesthesia was by intraperitoneal injection of Avertin 
(Tribromoethanol anaesthetic). This was used from a pre-prepared frozen stock of ; 
2.5g 2,2,2-tribromoethanol (Sigma-Aldrich), 5ml 2 methyl-2-butanol tertiary amyl 
alcohol; (Sigma-Aldrich); made up to 200ml with dH2O. This results in a slower onset 
of anaesthesia but the standard dose results in an approximate 30 minute long period 




2.4.4 Tissue collection 
At the end of the experimental period animals were sacrificed by an approved method. 
In animals undergoing bronchoalveolar lavage euthanasia was performed by the 
administration of a lethal dose of pentobarbitone and following the loss of reaction to 
painful stimuli the abdominal cavity was opened and the animal was exsanguinated by 
aorto-caval transaction. 
Tissue was collected for further study by the following methods 
 
Bronchoalveolar lavage 
Once the animal was dead the thoracic cavity was opened to expose the contents. The 
trachea was exposed and cannulated with a section of polyvinyl chloride tubing 
(0.67mm internal diameter). 0.8ml of cold PBS was then slowly instilled three times 
to lavage the lungs. The first lavage was kept separate from lavages 2 and 3 to allow 
the supernatant to be kept for subsequent cytokine analysis. From lavages 2 and 3 
only the cells were retained for analysis. Lavages were kept on ice until further 
processing in the laboratory.  
In order to minimise the risk of contaminating the BAL contents the animals were 
exsanguinated prior to BAL in order to achieve a bloodless field during the neck 
dissection. It was decided that flushing the vasculature was not appropriate prior to 
BAL in order to minimise pulmonary tissue trauma that can occur during the 
cannulation of the pulmonary artery and incision of the left atrium. Furthermore the 
release of intravascular fluid could contaminate the collected BAL fluid. In addition 
the flushing of the vasculature could dislodge intravascular features of ALI (for 
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example migrating neutrophils, microvascular thrombi) and it was felt that the ability 
to see this features would be of benefit. 
 
Lung fixation 
Following BAL the heart, lungs and other mediastinal contents were removed en bloc. 
1 ml of fixative (10% neutral buffered formalin [Sigma Aldrich] or Methacarn [60% 
methanol 30% chloroform 10% glacial acetic]) was instilled and then the trachea was 
tied. The lung block was then submerged in fixative for 24 hours before processing 
and embedded in paraffin wax. Blocks were stored at lab temperature out of direct 
light. Sections for immunohistochemistry were cut at 3m thickness on a microtome 
and floated at 42
o
C prior to mounting on superfrost slides (BDH, Poole, UK). Slides 
were incubated overnight at 37
o
C and then stored at room temperature away from 
direct light. 
 
2.4.5 Bronchoalveolar lavage processing 
Both samples of lavage 1 and the combined sample of lavage 2 and 3 were 
centrifuged for 2 minutes at 500x G at 4
o
C. The supernatant from lavage 1 was 
decanted and kept for further analysis. The supernatant from lavages 2 and 3 was 
discarded. 
The 2 cell pellets were resuspended in a total of 500μl of PBS. The total cell count 
was then determined using the NucleoCounter (Chemometec, Sartorius, Surrey, 
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England) automatic mammalian cell counter system following the manufacturer’s 
instructions. 
A sample of the cell suspension containing approximately 2x10
5
 cells was then used 
to prepare slides (Superfrost) by centrifugation at 300rpm for 3 minutes (Cytospin 2, 
Shandon Instruments Pittsburgh, USA). After air drying the slides were stained using 
Diff Quik (Dade Behring Dudingen, Switzerland) again following the manufacturer’s 
recommendations. BAL cell differential counts were then performed using standard 
morphological criteria under a light microscope at 40x magnification. A total of at 





As a measure of alveolar capillary damage the lavage fluid protein concentration was 
determined using the BCA protein assay as described above. Samples were run in 
duplicate. BAL cytokine levels were measured using ELISAs as described above. 
 
2.4.6 Lung Myeloperoxidase assay 
As a measure of pulmonary neutrophil infiltration the level of myeloperoxidase 
(MPO) activity was measured in lung homogenate based on the method of Suzuki et 
al [155]. 
The right lung of some animals was snap frozen in liquid nitrogen and stored at -80
o
C 
until required. After thawing the lung was added to 1ml of 100mM Na2HPO4 pH6 
buffer and homogenised for 20 seconds. The homogenate was then centrifuged at 
10000 rpm for 15 minutes at 4
 o
C and the supernatant discarded. The pellet was 
resuspended in 300μl of Na2HPO4 and 0.5% Hexadecyltrimethylammonium bromide 
and homogenised on ice. The sample was then sonicated for 20 seconds and then 
frozen/thawed 3 times. Following a final centrifugation step at 10000rpm for 10 
minutes at 4
 o
C the supernatant was stored at -80
 o
C until used. 
The MPO assay was performed by measuring the colour change caused by the 
reaction of 10μl of supernatant with 140μl of TMB superfast substrate (Sigma). The 
colour change at 655nm was recorded over a 3 minute time period. This was 




2.4.7 Wet/Dry lung weight 
As a measure of pulmonary oedema the wet/dry weight of the lungs of some animals 
was recorded [156].  Briefly the left lung of the animal was removed and blotted dry 
and then weighed. It was then placed in an oven at 65
 o
C for 2 days. The dry weight 
was then recorded and the difference (wet/dry weight) was determined. 
 
2.4.8 Evans blue dye measurement for determination of pulmonary 
vascular permeability 
Evans blue dye has a high affinity for albumin and binds stably to it seconds after 
plasma injection. The measurement of dye deposition in organs can therefore be used 
as a measure of vascular permeability in animal models[156]. 
Animals were injected intravenously with 20mg/kg of Evans blue (Sigma) dye 30 
minutes prior to sacrifice. After sacrifice the pulmonary vasculature was flushed with 
saline until the fluid leaving the left atrium was clear. The lung was then homogenised 
in 1 ml of PBS to which 2ml of formamide was then added. The mixture was 
incubated overnight at 60
 o
C. Following this the sample was centrifuged at 2000xG 
for 30 minutes to remove cell debris. Evans blue in the lung tissue
 
was quantitated by 
dual-wavelength spectrophotometric analysis
 
at 620 and 740 nm (Sue et al 2004). This 
method corrects the specimen’s
 
absorbance at 620 nm for the absorbance of 
contaminating heme
 
pigments, using the following formula: corrected absorbance
 
at 
620 nm = actual absorbance at 620 nm – (1.426 (absorbance
 




Protocols varied with antibody utilised. The common core protocol is described below 
and variations from this are described under specific antibody headings. 
General Protocol 
Methacarn fixed paraffin embedded sections were prepared for 
immunohistochemistry by dewaxing in xylene (Genta Medical, York, UK), where 
slides were submerged for 2x5minutes, followed by 1 minute submersions in 100%, 
70% & 50% methylated spirit (Genta Medical) for serial rehydration to water. From 
here slides underwent antigen retrieval with antigen unmasking solution (Vector, CA, 
USA) where 5mls is added to 500mls of water in a plastic container, slides are then 
submerged and microwaved on full power for 3x5 minutes. Slides were then cooled 
for 20 minutes in flowing tap water. This was then followed by a peroxidase blocking 
step, where slides were incubated in a 2% H2O2 solution (Sigma-Aldrich) for 15 
minutes, then washed in PBS for 2 minutes.  
 
Slides were then loaded into Sequenza coverplate clips (Thermo Shandon, Cheshire, 
UK), which allow use of small 125l volumes to cover sections through utilisation of 
capillary action across the surface of the slide. Reagent deliveries to these clips were 
separated by two to three full PBS washes.  
 
Once the Sequenza was loaded, slides were biotin and avertin blocked using a Vector 
kit. Three drops of each (approx 125µl) were applied for 15 minute room temperature 
incubations, separated by PBS wash steps. This was then followed by the specific 
primary antibody. For rabbit polyclonal antibodies the Dako EnVision system (Dako 
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Cytomation, CA, USA) was then used to detect antibody binding using 3 drops of the 
labelled polymer. After 30 minutes incubation and 3 washes with PBS this was 
followed by use of the diaminobenzidine (DAB) chromogen development systems 
(Dako Cytomation, CA, USA), where 1 drop of concentrate was added per ml of 
supplied buffer and administered to sequenza for 5 minutes at room temperature. 
Slides were then counter stained in haematoxylin (Shandon/Thermo) for 5 seconds (to 
stain the nucleus) and rinsed in tap water for 5 minutes. This was followed by 
submergence in Scot’s tap water (Sodium bicarbonate 17.5g, magnesium sulphate 
100g (Sigma-Aldrich), five litres of water) for 1 minute. Slides were then rinsed in tap 
water and dehydrated through three alcohols and three xylenes, 1 minute each, prior to 
cover slip addition with DPX mountant. 
 
Nitrotyrosine IHC 
Anti-nitrotyrosine rabbit polyclonal antibody was supplied by   Upstate cell signalling 
solutions (Lake Placid, NY, USA). This antibody has been raised against nitrated 
Keyhole Limpet Hemocyanin. For IHC protocols the antibody was used at a final 
concentration of 5μg/ml. Incubation  was performed at 4
o
C overnight. 
To confirm specificity of the staining positive control slides were generated by 
incubating uninjured lung sections with peroxynitrite (catalog # 20-107). After the 
tissue section was deparaffinised, the slide was covered with a drop of PBS, pH 7.4 
into which 10 microliters of peroxynitrite solution was mixed. Negative controls were 
prepared by omission of the primary antibody. To further confirm specificity of 
staining the primary antibody was blocked by incubation with a 10mM nitrotyrosine 





Rabbit polyclonal anti Cre (EMD Chemicals) was used at a final concentration of 
5μg/ml. This antibody was raised against the 35kDa bacteriophage P1 Cre 
recombinase. Primary antibody was incubated for 1 hour.  
 
Hif-1α IHC 
This was performed using a rabbit polyclonal antibody (Cayman Chemicals, Ann 
Arbor, Michigan, USA) raised against the C terminal amino acids 809-826 of Hif-1α. 
It cross reacts with mouse and human protein. Antibody was used at a final 
concentration of 0.5μg/ml. To allow detection of this protein a modified protocol was 
followed. Antigen retrieval was performed using Borg Decloaker (BioCare Medical 
Concord, Califonia, USA) in a microwave pressure cooker. After overnight incubation 
with the primary antibody a biotinylated goat anti-rabbit antibody (Dako) was 
incubated for 40 minutes at a final concentration of 6μg/ml. Bound secondary was 





This was done using the Hypoxyprobe-1 Plus system for the detection of tissue 
hypoxia (Chemicon International, Temecula, California, USA). This system uses the 
ability of a nitroimidazole compound, pimonidazole, to bind irreversibly to hypoxic 
proteins. Animals were injected with 30mg/kg of pimonidazole intraperitoneally 30 
minutes before an experimental procedure. 
Sections for immunohistochemistry was prepared as described above. Following the 
manufacturer’s protocol pimonidazole binding was then detected by incubation with a 
FITC-labelled mouse anti-pimonidazole antibody at a concentration of 50μg/ml. A 
supplied HRP conjugated anti-FITC antibody was then used as secondary antibody at 
50μg/ml final concentration.  
 
2.5 Alveolar macrophage culture 
BAL was performed as previously described. However, in order to maximise AM 
recovery 5 separate washes of 0.8ml of saline were used and lungs were gently 
massaged with blunt forceps. Isolates were pooled and kept on ice at all times to 
reduce cellular activity and macrophage loss through adherence to the bijou. The 
expected yield was1-2x10
5
 cells per animal. 
AM extracts were centrifuged at 300xg for 10minutes at 4
o
C and the resulting pellet 
re-suspended in RPMI plus 10% FCS, 2mM L-glutamine, 50μM β-mercaptoethanol  
and 100U/ml penicillin and 100μg/ml streptomycin . Cells were plated with 
2x10
5
cells/well in a final volume of 1 ml medium. 
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Plated AM were left for 1-2 hours to adhere then the original medium was removed 
including contaminating red blood cells and replaced with fresh medium.  
 
2.6 Bone Marrow Derived Macrophages 
Bone Marrow derived macrophages (BMDM) were derived by standard techniques 
used in the CIR. Briefly mice were sacrificed by a schedule 1 approved method. The 
animal was then bathed in 70% ethanol, de-trousered and the femurs were removed by 
dissection. Care was taken throughout to avoid damage to the bone. The bone was 
then placed in cold PBS plus Pen/Strep and stored on ice until returned to the 
laboratory. Under sterile conditions the bones were then washed with 70% ethanol 
and remaining muscle was removed from the bone. The bone was then cut through 
both epiphyseal plates and using a 25G needle the marrow contents were flushed into 
a universal pot. Medium composed of  Gibco’s DMEM/F12 Glutmax, with 10% FCS, 
and Penicillin 100U/ml and Streptomycin 100μg/ml and 20% L929 medium (see 
below) was used to flush the marrow content. The cells were then resuspended by 
pipetting in the medium. The cells from one animal were then cultured in a 60ml 
Teflon pot for 7 days in a total of 40 ml medium. Half the medium was changed every 
2 days and replaced with fresh medium with care taken to avoid removing cells. 
After 7 days culture the cells were collected by centrifugation and then used in 
experiments. BMDM were maintained in RPMI plus 10% FCS and Pen/Strep for 
experiments. 
The Murine fibrosarcoma cells, L929, spontaneously secrete into culture supernatant 
colony stimulation factor (M-CSF or CSF-1). The fibroblasts are grown in T162 
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flasks in 25 ml of DMEM medium. The supernatant is harvested 3 days after they 
reach confluency; filtered, aliquoted and stored at -80C until the day it is added as a 
supplement to the growth medium. (The cells are split 1:30 and replated for future 
supernatant collection).  
 
2.7 DNA extraction 
For quantitative PCR cells of interest were cultured as described above. DNA was 
extracted using Direct PCR lysis reagent (Cell) (Viagen Biotech Inc, Los Angeles, 
California, USA). Briefly cells were lysed by the addition of lysis reagent containing 
proteinase K (Sigma). They were then incubated for 5 hours at 55
o
C. 1μl of lysate was 
then used per PCR reaction as per manufacturer’s recommendation. 
 
 
2.8 Quantitative Polymerase Chain Reaction 
In order to determine the deletion efficiency in alveolar macrophages of the cre 
recombinase in the Hif mice the presence of the Hif-1α gene in genomic DNA was 
compared between cre negative and cre positive animals. (Cramer et al 2003). In this 
assay the level of Hif-1α gene is compare to that of a reference gene (Haem 




This assay was performed with the help of Dr Matthew Sharp BRR Little France. HO-
1 was chosen as the reference gene as this is the in-house positive control gene that 
the BRR facility uses to check all its PCR runs. 
The PCR reaction was run on an ABPI7000 sequence detection system under standard 
realtime PCR conditions. 
The reaction was performed in a final volume of 25μl 
The reaction mixture comprise of 
Abegene Absolute QPCR Rox mix (x2)  12.5μl 
 Primer/Probe Mix (x25)    1μl 
Nuclease free water     10.5μl 
DNA       1μ 
The Hif-1 primers were designed using the Roche Universal Probe assay design 
centre (www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp). Probe 60 from the 
Universal probe set was used. 
The HO-1 and Hif-1 assay were run in triplicate in separate wells. The CT for Hif-1 
and HO-1 were determined and the fold difference in gene DNA was calculated using 
the Comparative CT method (ΔΔCT). Representative results for a wild type and 









b. Hif-1α knockout macrophages 
 
 
Figure 2-2 Representative PCR results from wild type (graph a) and hif-1 knock out 
alveolar macrophages. Each graph shows triplicate results for HO-1 (used as reference 
gene, left hand triplicate) and Hif-1 (gene of interest, right hand triplicate). It can be 
seen that there is an increase in the cycle number in the knock out animal before hif-1 








2.9 Genomic PCR 
To confirm the presence of cre and the floxed alleles in our mice genomic PCR was 
performed. This was done on ear clip samples obtained by the BRR staff. DNA was 
extracted by the BRR facility staff using DirectPCR lysis reagent (Mouse ear) 
(Viagen). 
For genomic PCR primers were designed by Professor R Johnson’s team and they 
kindly supplied the protocols for the assays 
Hif-1 PCR 
Forward primer: TGC AAG TTG AAT AAC CGG AAA 
Reverse primer: CTA GAG CCT GTT TTG CAC GTT C 
The reaction mix used was as follows: 
DNA   1μl 
X10 buffer  5μl 
MgCl2 (25mM) 2μl 
dNTPs (10mM) 1μl 
Forward (100pM) 1μl 
Reverse (100pM) 1μl 
Taq polymerase 0.5μl 
Nuclease free H20 38.5μl 
Total volume   50μl 
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The reaction conditions were 
1minute 45seconds  94
o
C 
25 secs  94
o
C 
45 secs  57
 o
C repeat 36 times 
60 secs  72
 o
C 
Samples were run on a 2.5% agarose gel and visualised on the Versadoc imaging 
system. 
Primers were synthesised by Eurofins MWG Raynes Park 
London. Taq DNA polymerase, deoxynucleosides (dNTPs) and nuclease free water 
were obtained from Promega (Promega Corp, Madison, WI, USA). 
 
2.10 Statistical Analysis 
Cell culture results were analysed by repeated measures ANOVA with Bonferroni's 
Multiple Comparison Test. The data were confirmed to be normally distributed using 
the D'Agostino & Pearson omnibus normality test.  
Animal data sets were analysed with the Mann-Whitney test as normality could not be 
proven. All statistical tests were performed with GraphPad Prism v5.01 (GraphPad 




For in vitro experiments cells were cultured in triplicate and the average was used as 














Development of a Model of Acute 






Major trauma is a common cause of Acute Lung Injury (ALI) recognised clinically as 
the Acute Respiratory Distress Syndrome (ARDS). At the time of injury trauma 
patients suffer a number of simultaneous insults which may lead to the development 
of ALI. These include hypovolaemic shock as a result of massive haemorrhage; tissue 
hypoxia secondary to impaired ventilation and reduced mixed venous PaO2 resulting 
in reduced arterial PaO2; long bone fractures and soft tissue injury; aspiration of 
oropharyngeal and gastric contents and visceral injury with release of potentially 
injurious contents (e.g. faecal matter). Furthermore if the patient survives, more 
insults including fluid resuscitation, artificial ventilation and surgery may precipitate 
ALI. 
In order to study the role of these multiple factors it is necessary to first look at each 
in isolation in order to allow the researcher to gain a clear understanding of the 
pathogenesis of ALI. This led to the study a number of injurious insults which may 
lead to ALI in mice.  
In general terms, models used in this field can be divided into 2 categories. They can 
either result in lung injury that mirrors that seen in humans, with histological evidence 
of alveolar neutrophilic infiltration and oedema and widespread epithelial and 
endothelial damage. Alternatively, models can involve the use of a stimulus that is 
thought to be involved in the generation of ALI and the early cell signalling effects 
can be studied. In these experiments there is often minimal evidence of lung injury, 
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either because the stimulus is of a subclinical severity or the animals are sacrificed at 
very early time points before injury is apparent. In this work the aim was to develop a 
model which clinically and microscopically results in a pattern of injury similar to the 
human disease as this confirms the relevance of the insult and potentially allows direct 
extrapolation of results to human studies. 
Therefore, the aim of this piece of work was to develop a model of ALI which 
provides a suitable tool with which to study the role of myeloid cell Hypoxia-
inducible factor 1 in the development of ALI.  
In order to be worthy of further study the following conditions had to be fulfilled: 
- the model must result in a disease process similar to that seen in patients 
- the initiating insult must be clinically plausible 






3.2 Fixed Volume Haemorrhagic Shock Model 
 
Haemorrhagic shock (HS) has been reported to cause ALI in animal models in mice, 
rats and other species[157-159]. There are two possible approaches to the 
development of an HS model in animals. Either, the animal can have a variable 
volume of blood removed sufficient to reduce arterial blood pressure to a 
predetermined level for a fixed period of time (fixed pressure model) or a 
predetermined volume of blood is removed over a fixed period of time (fixed volume 
model) and in this case blood pressure is a dependent variable. 
There are several advantages to the second model. Firstly, it more closely resembles 
the clinical situation[160] where a patient loses a proportion of their circulating blood 
volume but both the body’s homeostatic mechanisms and subsequent medical efforts 
are directed at restoring blood pressure to near normal as quickly as possible. In 
addition it does not require more invasive monitoring of the animal which results in 




Male FVB/NJ mice were anaesthetised with 5% Isoflurane in oxygen before being 
restrained in a supine position on a heated mat, anaesthesia was then maintained with 
1% Isoflurane in oxygen. A 29 gauge heparinised needle connected to a syringe was 
inserted into the heart by a sub-xiphisternal approach with the tip of the needle 
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directed towards the animal’s left scapula. Gentle aspiration was maintained on the 
syringe until blood was aspirated. A predetermined volume of blood was then 
removed and the animal was allowed to recover in its cage. Recovery occurred within 
5 minutes of the end of exposure to anaesthesia. Sham animals were anaesthetised and 
a cardiac puncture was performed but no blood was removed. 
 
3.2.2 Results 
In line with previous investigators the effect of removing 30% of calculated 
circulating blood volume (0.025ml/g body weight) was studied. A total of 27 animals 
underwent the 30% shock protocol. There was 1 death before the specified timepoint 
(3.7% mortality) which occurred a few minutes after the procedure without the animal 
recovering consciousness. Post-mortem examination revealed the cause of death to be 
massive haemothorax. 
In line with Abraham’s group[157] animals were allowed to recover for 1 hour after 
HS before sacrifice and lungs were removed for histological analysis. In none of the 
animals was there evidence of ALI when assessed by a Veterinary pathologist (Dr 
David Brownstein). 
Abraham’s group [157;161] has also reported an increase in lung myeloperoxidase (a 
measure of neutrophil content) and lung wet/dry weight ratio (a measure of 
pulmonary water content) in mice following HS. Consequently the effect of 30% HS 
on this two markers was studied at 4 hours, a later timepoint which has been reported 
as the peak injury by a group from the same laboratory. The combined results of two 
independent experiments are shown in Figures 3-1 and 3-2. At this 4 hour timepoint 
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there was no evidence of neutrophil accumulation or increased lung water content in 
the HS group. This was confirmed by histology from a further animal. 
 






















Figure 3-1 Effect of Haemorrhagic Shock (HS) on Lung Myeloperoxidase activity at 4 
























Figure 3-2 Effect of Haemorrhagic shock on lung wet/dry weight at 4 hours. Error bars 





To determine if there was any evidence of tissue injury at a later timepoint or if a 
more severe insult could induce injury two further studies were undertaken. First after 
30%HS mice were allowed to survive for 8,12,24,48 and 72 hours (n=1 at each 
timepoint) and the lungs removed for histological analysis. Again there was no 
quantifiable evidence of pulmonary injury at any timepoint.  
Finally a group of animals underwent 40%HS, a more severe insult. This insult was 
associated with a 33% (3 of 9 animals) instant mortality (2 animals dying as a result 
of massive haemothorax and 1 undetermined cause). Animals were sacrificed at 1, 4 
and 8 hours and 3 and 5 days. At no timepoint was there any histological evidence of 
pulmonary injury. 
Therefore fixed volume survivable haemorrhagic shock at 30% or 40% of circulating 





The reason for the differences between the observed data and Abraham’s group 
[157;161-164] is unclear. The mortality quoted in their papers for their 30% HS 
protocol is 10-12%, significantly higher than the 3% seen in this study, suggesting 
that their insult is somehow more severe than that used here. Furthermore the exact 
nature of the pulmonary injury seen by Abraham’s group is debatable. They show an 
increase in total lung MPO a measure of PMN number in lung tissue but this does not 
describe the cells’ position. ARDS is characterised by a neutrophil rich alveolitis 
which Abraham’s data do not support, their histology shows PMNs mainly in the 
pulmonary vasculature and some in the alveolar interstitium.  
The observed difference may also relate to the animal facility used. These 
experiments were conducted in the University of Edinburgh’s new animal facilities at 
Little France which have a significantly lower infectious agent load than the older 
facilities used and have resulted in the need to redesign other inflammatory rodent 
models (Dr P. Fitch personal communication) suggesting that the microbiological 
environment of the animals could have an effect on their inflammatory response. For 
example, the release of LPS from ischaemic bowel after the insult may play a role in 
the generation of ALI although this mechanism has been questioned[165] in a model 
of HS which failed to show any change in plasma endotoxin levels after HS. 
Alternatively, the differences may reflect physiological differences between the 
strains of mice used [166]. Abraham’s group use BALB/c or C57 Black6 mice while 
this study used the FVB/NJ strain. This strain was chosen because of the potential for 
collaboration with other groups in the Centre for Inflammation Research which use 
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the FVB/NJ strain in other models of organ injury and is recognised to respond 
differently to other strains when exposed to other insults. 
Other groups[167] have shown similar results to the observed data when studying 
models of haemorrhagic shock. They have found that HS “primes” the animal to a 
subsequent second insult such as systemic or local sepsis resulting in exaggerated 
pulmonary damage but that on its own it does not lead to evidence of pulmonary 
dysfunction either by histological assessment or by measuring pulmonary MPO levels 
or lung water content. It was felt that studying ALI initiated by a single insult was 
most likely to generate data that allowed dissection of the pathways involved. 
Therefore, this study did not further investigate the effect of a second insult on the 




3.3 Hypoxia as a potential trigger for ALI 
 
Lung hypoxia can be seen in critically ill patients. Trauma patients hypoventilate as a 
consequence of direct thoracic trauma or an altered level of consciousness following 
cerebral injury. Other groups of patients develop regional atelectasis with subsequent 
hypoxia as a result of pain, impaired cough or direct compression of lung parenchyma 
(e.g. pleural effusion) [168].  
Hypoxia is a central component in the development of High Altitude Pulmonary 
Oedema [60-62] usually seen in mountaineers at heights over 3000m above sea level. 
These patients develop pulmonary oedema in the presence of normal left ventricular 
function, similar to the situation in ARDS. 
Acute hypoxia has been reported to alter release of mediators such as cytokines, 
neuropeptides and surfactant components by pulmonary inflammatory and 
parenchymal cells which may result in lung injury. 
As part of the study of the multiple hits that trauma patients are exposed to I therefore 
studied the response of mice to a brief period of severe hypoxia relevant to the clinical 
situation seen in trauma patients, where, following the insult during the period of pre-
hospital care and before definitive airway management, usually in the Emergency 





FVB mice were exposed to hypoxia in a custom built Perspex chamber (Figure 3-3; 
Outer box 41x31x27cm; Inner box 31x21x20cm)) designed in accordance with Home 
Office requirements. An hypoxic gas mixture (94% Nitrogen, 6% oxygen; 
Cryoservice UK) was flushed through the chamber. Chamber oxygen levels were 
recorded using a paramagnetic oxygen analyser (Datex, UK), carbon dioxide was 
scavenged using soda lime and airflow was maintained by an electric fan. The 
chamber was filled with standard bedding and food and water were freely available. 
 




Using an initial flow rate of 15 litres/minute to purge the chamber an atmosphere of 
8% oxygen could be rapidly reached and then maintained with a flow rate of 2l/min 
for the remainder of the experiment (figure 3-4) 
 
Chamber Atmospheric Oxygen
















Figure 3-4 Representative recording of atmospheric oxygen from custom built chamber 




Animals were exposed to acute normobaric hypoxia for 4 hours. With this they 
showed increased respiratory rates (range 130-200 breaths/min), piloerection, mild 
hunching and reduced activity. They continued to eat and drink. Mortality was 6% 
(n=17). Overall the severity of this procedure was moderate/severe as defined by the 
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Home Office. Therefore if further insults were to be added (e.g. haemorrhage) a 
higher atmospheric oxygen level would have to be employed. 
Acute severe hypoxia has been reported to result in pulmonary neutrophil recruitment 
in some but not all studies. To assess neutrophil recruitment to the pulmonary 
compartment in this model pulmonary MPO was measured in some animals. 4 hours 
of acute hypoxia did not change the pulmonary MPO level compared to control 
animals (control 0.1043 ± 0.02396 N=4 v hypoxic 0.1301 ± 0.03392 N=4 p=0.55 
graph). 
Similar levels of acute hypoxia have been reported to cause pulmonary oedema in 
animal models when assessed by varying techniques. I used two measures to study the 
development of pulmonary oedema in this model. First lung wet/dry (W/D) weight 
ratio was used as a measure of total pulmonary water content which increases in 
pulmonary oedema. The W/D weight ratio was not different between control and 
hypoxic animals (control 4.790 ± 0.2035 N=7 v hypoxic 4.935 ± 0.2664 N=7 p=0.67 
graph). In a separate group of animals vascular permeability was measured by the 
technique of Evans blue (EB) dye extravasation. Hypoxic animals showed a 
significant increase in EB extravasation over the 4 hour period (control E620 corr 
0.8033 ± 0.1105 N=3 v hypoxic 1.557 ± 0.1299 N=3 p= 0.01). The increase in 
vascular permeability but lack of frank pulmonary oedema was confirmed by 
histology (figure 3-5) which showed an increase in alveolar septal thickness but no 
alveolar oedema. Histology also showed thrombus formation in pulmonary veins 







Figure 3-5 Normal Lung from Control animal and Alveolar Septal Oedema visible from 













Alveolar hypoxia has been linked to the development of ALI. In my hands exposure 
to 8% oxygen for 4 hours leads to increased pulmonary vascular permeability in the 
absence of pulmonary neutrophilia. Others have reported a mild pulmonary 
inflammatory infiltrate in response to similar hypoxia in rats[65] although this finding 
has not been reproduced [170;171]. An increase in pulmonary vascular permeability 
has been a more consistent finding [65;172] while the development of pulmonary 
oedema has been reported by some [172;173] but not all authors [174;175]. Some of 
these differences may be species and strain related [154;176;177]. We chose a strain 
of mouse which most closely mimics the human cardiovascular response to hypoxia 
with a minimal hypotension response compared to other inbred mouse strains [154]. 
The mechanism of increased vascular leak is unclear. The increase may be due to 
increased endothelial permeability, increased capillary pressure or both. Acute 
hypoxia causes pulmonary arterial vasoconstriction which increases capillary 
pressure. However other substances such as an increase in the neurotransmitter 
Substance P and its receptor NK-1 have been reported in acute hypoxia and can result 
in increased vascular permeability and vascular pressure [174]. Other putative 
mechanisms include an increase in adenosine generation by pulmonary cells leading 
to increased endothelial permeability by a cAMP dependent pathway [172;178] or the 
release of pro-inflammatory cytokines by resident alveolar macrophages in response 
to hypoxia[63]. A further possibility is the effect severe hypoxia may have on lung 
biomechanics. Minko et al [173] have shown that hypoxia results in a change in 
pulmonary lipid composition, the major component of surfactant, and have proposed a 
role for this in the generation of lung injury. An increase in respiratory rate is a 
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consistent finding in studies and the mechanical effects of this have not been 
explored. Studies of any alteration in barrier function are required to assess the effects 
on the lung of operating at an increased frequency but smaller tidal volume, a 






3.4 Systemic Endotoxin as a trigger for ALI 
 
ALI is a frequent complication of severe sepsis and has a high mortality associated 
with its development. Sepsis can develop in critically ill patients either as their initial 
insult (e.g. meningococcal sepsis) or as a second insult such as peritoneal infection 
following abdominal trauma or bacteraemia associated with medical interventions 
including venous access devices. One of the proposed key triggers in the pathogenesis 
of sepsis is endotoxin, (Lipopolysaccharide [LPS]), a component of the cell wall of 
Gram negative organisms. With the absence of key features of ALI in the previous 
models we aimed to determine whether systemic administration of endotoxin would 
provide a useful model of ALI in our hands. 
 
3.4.1 Method 
Based on published data [179-181] a dose of 15mg/kg of Escherichia coli LPS 
serotype B127:08 (1mg/ml dissolved in PBS) was given by intraperitoneal (i.p.) 
injection to conscious mice in a final volume of 500μl. Doses of 10-25mg/kg have 
been shown to induce pulmonary neutrophil infiltration [182] in this strain. Similar 
doses have been shown to induce neutrophil infiltration of other organs [152]; 
stimulate the release potentially important cytokines [146]  and induce metabolic 
changes [150] characteristic of sepsis with no observed mortality. Animals were then 
place back in their cage and allowed free access to food and water before sacrifice. 




Animals given i.p. LPS exhibited obvious features of systemic upset. Within 1 hour 
they displayed piloerection; a hunched posture; narrowed eyes and reduced 
spontaneous movement and self-care. These features persisted to the end of the 
experiment. 
LPS administration resulted in a significant increase in pulmonary MPO levels 
compared to control animals (LPS group 6.008 ± 0.2952 N=4 v control 3.271 ± 
0.3464 N=5; p=0.0007).  
There was no difference in pulmonary wet/dry weight between groups at this 
timepoint (control 4.789 ± 0.07491 N=5 v LPS 4.929 ± 0.08286 N=4 p=0.25). 
Histology of sections showed neutrophil congestion and margination in alveolar 
capillaries and thickening of alveolar walls but there was no evidence of alveolar 





Figure 3-7 Histological Sections from Animals given intraperitoneal LPS and sacrificed 





This experiment confirmed that systemic administration of LPS results in pulmonary 
neutrophil sequestration in the vasculature but at the timepoint studied showed no 
evidence of pulmonary oedema, alveolar haemorrhage or airspace inflammatory cell 
infiltrate important features of ALI were seen. Others have shown pulmonary oedema 
at this timepoint [157;181] accompanying an increase in pulmonary MPO content at 
similar and lower doses of LPS. However some investigators have failed to show 
pulmonary airspace neutrophilia over periods of up to 4 days [183;184] following 
systemic LPS. Interestingly Steinmuller et al [184] showed a large, persistent increase 
in bronchoalveolar lavage MIP-2 levels despite a lack of neutrophil alveolitis 
suggesting that even though systemic LPS can lead to high local levels of neutrophil 
chemoattractants the injury generated may not be enough to stimulate neutrophil 
migration into the airspace. 
The animals given this dose of LPS exhibited marked illness behaviour and signs of 
distress. Given the nature of the observed pulmonary neutrophilia and the lack of 
consistent alveolitis found by other investigators it was felt that the burden placed on 
the animals during the experiments did not justify continuing to use this model and I 





3.5 Pulmonary Instillation of LPS as a model of ALI 
 
The direct exposure of rodent lung to injurious stimuli including LPS and IgG 
immune complexes has been used to model ALI [185;186]. Techniques to deposit the 
agent into the lung include inhalational exposure by nebulising the agent [187]; 
intranasal administration and subsequent inhalation [188]; aspiration of the agent from 
the oropharynx or direct tracheal instillation either following surgical tracheotomy 
[189] or intubation of the trachea through the vocal cords [190]. Although it may not 
reflect the entire complexity of ALI, instillation of LPS has been widely used as a 
model of ALI because of its clinical relevance with the frequently seen important role 
of Gram negative bacteria in initiating lung injury and the resultant injury exhibiting 
the key features of ARDS with a neutrophil rich alveolitis developing with damage of 
the alveolar-capillary barrier resulting in a protein rich alveolar exudate. 
Two methods of depositing LPS into mouse lung were studied in this work. 
 
3.5.1 Oropharyngeal aspiration model method 
Aspiration of material from the oropharynx is used in the CIR as a method of inducing 
ALI. Animals are anaesthetised by exposure to 5% Isoflurane and then suspended by 
their incisors from a custom built stand (figure 3-5). The animals tongue is then 
grasped and pulled forward to try and prevent deposition of the agent in the 
oesophagus. A 50μl volume of solution in then deposited in the back of the 
oropharynx and as the animal breathes the solution is aspirated into the trachea and 
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deposited in the lungs. The animal is then allowed to recover. With this technique the 
period of anaesthesia is short, usually 2-3 minutes total. 
3.5.2 Tracheal intubation method 
 
The second technique used was based on a method of endotracheal intubation of 
rodents [191]. The mouse was anaesthetised with an i.p. injection of Avertin. It was 
then suspended by its top incisors on the same support stand and the trachea was 
trans-illuminated by a cold light source (figure 3-6). The mouth was held open by a 
weight suspended from the lower incisors and the tongue was pulled forward. A 
sterile guide wire (0.8mm OD, Vygon UK) was then inserted into the trachea under 
direct visualisation. A 22G cannula was then passed over the wire and into the 
trachea. The guide wire was then removed and the animal allowed to breathe through 
the cannula. (Figures 3-7 to 3-9) Correct placement of the cannula could be confirmed 
by transient obstruction of the end of the cannula and the animals breathing pattern 
would be seen to change. 50μl of solution was then pipetted into the cannula and the 
mouse would inhale the solution. The cannula would be removed after complete 
inhalation of the solution (usually about 10 breaths) and the animal would be allowed 





Figure 3-8 Support stand used for Pulmonary Instillations. 
 













3.5.3 Results of oropharyngeal aspiration and tracheal intubation 
methods 
Initially the oropharyngeal technique was used. Instillation of 50μg of LPS in 50μl of 
saline resulted in an intense neutrophilic alveolitis at 6 hours.  BAL total cell number 
increased from 218800 ± 45480 (N=4) in saline instilled animals to 516900 ± 61860 
(N=4). This increase was due to an increase in alveolar neutrophil number (control 0 v 
LPS 438294±68448) and a decreases in alveolar macrophage number (saline 218800 
± 45480 v 74140 ± 9996) similar to previous authors findings (Asti et al 2000). 
Further as a measure of interstitial neutrophil accumulation lung homogenate MPO 
was measured after BAL and was also increased in LPS treated animals (saline 0.7430 
± 0.1024 v LPS 5.233 ± 0.3568 ΔOD/min/g lung p< 0.0001). There was no difference 
in BAL total protein at this time point (saline 294.1 ± 39.35 v LPS 324.1 ± 42.66 
p=0.6).Thus direct injury of murine lung by instillation of LPS results in a 
neutrophilic alveolitis similar to ARDS. It also results in an increase in parenchymal 
neutrophils that are not accessible by BAL at this time point and likely represents 
cells trafficking from the vascular compartment to the alveolar space (Reutershan et al 
2005) 
However, when this experiment was repeated again a different pattern of injury was 
seen. On this occasion there was no difference in total cell number (saline 297800 ± 
145000 N=4 v LPS 376000 ± 165100 N=3, p=0.7); macrophage number (saline 
101900 ± 9475 N=4 v LPS 58340 ± 17290 N=3, p=0.06) or PMN number (saline 
195600 ± 151000 N=4 v 401600 ± 238900 N=3, p=0.5). The lack of difference was 
due to an increase in PMN in the saline treated group as there was no difference 
between PMN number in LPS treated animals (expt 1 438300 ± 68450 N=4 v expt 2 
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401600 ± 238900 N=3, p=0.87). Study of cytospins of BALS from saline treated 
animals revealed the presence of a spectrum of both Gram positive and negative 
bacteria suggesting that the aspiration technique allows the carriage of oropharyngeal 
flora into the lung during the aspiration leading to an alveolitis in control animals. 
Hence although this technique demonstrates that inhalation of LPS leads to ALI the 
magnitude of the effect could be hidden by the confounding effect of aspiration of the 
resident oropharyngeal flora, therefore a direct intratracheal instillation technique was 
developed. 
Initial attempts at intratracheal instillation either using a blunted 25G needle attached 
to a syringe or a fine gel-loading pipette tip attached to a pipette were unsuccessful 
because of an inability to identify successful tracheal intubation and were abandoned. 
The technique described above using a modified Seldinger technique which is used 
for many medical procedures proved easy to learn, reliable and avoided complications 
seen with other techniques for direct instillation such as mild alveolitis following 
surgical tracheotomy [192]. Preliminary studies using instillation of Evans blue dye as 
a marker of fluid deposition confirmed tracheal deposition and pulmonary spread of 
solution in animals occurring rapidly before sacrifice after 5 minutes (Figure 3-11). 
They also showed no deposition of any blue dye in the oropharynx therefore avoiding 





Figure 3-12 Lung Block and Section of Lung showing Deposition of Evan's blue dye 




This technique therefore became the standard method for instilling LPS into the lungs 
of animals for the remainder of the project. In a group of C57 Black 6 mice studied at 
24 hours instillation of LPS resulted in an intense neutrophilic alveolitis (Total cell 
count Saline 196500 ± 9186 N=4 v LPS 1787000 ± 132400 N=5 p< 0.0001; PMN 
count Saline 922.8 ± 347.9 N=4 v LPS 1507000 ± 122900 N=5 p< 0.0001) in treated 
animals associated with a loss of alveolar capillary integrity reflected by an increase 
in BAL protein content (Saline 157.9 ± 6.227 N=4 v LPS 468.5 ± 76.92 N=5 
p=0.0093).  Histology confirmed the movement of neutrophils into the alveolar space. 
This was accompanied by the development of a protein rich eosinophilic exudate and 
in some alveoli the movement of erythrocytes into the alveolar space as a result of the 





Figure 3-13 Intratracheal administration of LPS results in lung injury. Picture A 
Normal mouse lung. Pictures B 24 hours post-LPS instillation there is the development 
of neutrophilic alveolitis with free erythrocytes visible in one alveolus. Picture C Again 
at 24 hours post-instillation in some alveoli there is the accumulation of a proteinaceous 
exudate as a result of increase permeability of the alveolo-capillary barrier. Pictue D At 
5 days post instillation the intense neutrophil infiltrate persists and there is thickeniong 
of the alveolar septae. x200 Graticule=100μm. 
 
3.5.4 Discussion 
This study has confirmed that direct instillation of LPS by two techniques results in a 
pattern of lung injury in mice that reflects the pathological findings of ARDS in man. 
Similar results have been shown by other investigators [187;192-194]. 
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The advantage of the adopted tracheal intubation technique over the other techniques 
tried here and described in the literature include: absence of contamination of the 
instillate with oropharyngeal bacteria; minimal trauma compared to surgical 
tracheotomy; lack of any pulmonary barotrauma resulting from forced expulsion of 
liquid from the syringe or pipette as the animal inhales the liquid through the cannula 
and most importantly ease and reproducibility of the technique. 
The dose of LPS routinely used in this study is 50μg in 50μl of Saline. This is at the 
higher end of the dose range used in the literature although higher doses have been 
reported [148]. Liaudet et al [193] used this dose and were able to show a reduction in 
injury with concomitant administration of inosine suggesting that the dose does not 
represent an overwhelming supramaximal stimulus. However, it does represent a 
severe injury leading to some of the changes seen in human samples from patients 
with ARDS.  
It is appreciated that no single animal model fully represents the changes seen in 
humans however, the intratracheal endotoxin model does mimic a number of the 
changes seen: pulmonary neutrophil infiltration with movement of neutrophils from 
the intravascular space to the interstitium and then into the alveolus; accumulation of 
protein rich fluid in the alveolar space (although hyaline membranes were not seen in 






This chapter has been concerned with the development of an animal model of Acute 
Lung Injury. To be suitable the model needed to fulfil several criteria: 
- the model must result in a disease process similar to that seen in patients 
- the initiating insult must be clinically plausible 
- the model must be reproducible by other groups 
It was also preferable that the model relied on a single insult (e.g. haemorrhagic shock 
rather than haemorrhagic shock and resuscitation) so that the pathways resulting in 
organ injury can be more easily studied in future work. 
The results of the work are summarised in table 3-1. 
Table 3-1 Summary of Injury Pattern seen after differing Insults 
  Injury pattern  









shock No No No 
Acute Hypoxia Yes No Yes 
Systemic LPS Yes No No 
Intratracheal LPS Yes Yes Yes 
Histological injury*- in this body of work this refers to a microscopic pattern of injury which is composed of some of 
the features seen in human ALI. As discussed in the individual model sections this includes the presence of alveolar 
neutrophils; interstitial neutrophil accumulation; alveolar septal oedema; microvascular thrombi, accumulation of 
alveolar proteinaceous fluid and intra-alveolar haemorrhage [195]. 
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Using a number of models reported to generate ALI in the literature I found that direct 
tracheal instillation of LPS fulfilled the above criteria. It results in a neutrophilic 
alveolitis with an associated loss of alveolar-capillary barrier function. Aspiration of 
Gram negative bacteria or their cell wall components is a common insult in patients 
with ARDS and delivery of LPS to the alveolus has been reported by a number of 
groups in a range of species (including mouse and rat) to lead to ALI. 
The lack of injury following some of the reported techniques and the possible reasons 
for this has already been discussed. Future work could study other mouse strains to 
see if they develop ALI in response to those insults in our laboratory. However, the 
lack of tissue injury seen by other authors (e.g. Ayala 2002 [167]) in similar models 
supports the observed data.  
The hypoxic exposure model does result in the development of increased pulmonary 
vascular permeability and may in the future be useful in studying the response to 
severe hypoxia in settings such as adaptation to high altitude exposure but is not 
suitable for the current piece of work. 
The usefulness of the model of LPS injury is increased by the ability to replicate it in 
vitro by exposing cultured cells to the same insult and then studying the response of 
individual cell types. Such work helps to identify the source of important mediators 
that may result in tissue injury and test possible therapeutic interventions. 
Using both in vivo and in vitro techniques the remainder of this thesis will be 















Hif-1 mediation of the inflammatory 




The alveolar macrophage is a key cell in the detection of and response to pulmonary 
pathogens. It is located in a prime position to interact with pulmonary insults and 
functions as part of the lung innate immune response (phagocytosis; release of nitric 
oxide; secretion of cytokines) and also as part of the acquired response acting as an 
antigen presenting cell[196].  
The importance of alveolar macrophages in the generation of ALI has been confirmed 
in a range of injury models by selective depletion of these cells which results in 
reduced lung injury[76;77;197;198]. 
The alveolar macrophage is exposed to alveolar oxygen levels (approximately 14kPa 
[199]) and therefore is unique among tissue macrophages in residing in a niche where 
oxygen is abundant, the intracellular pO2 of the alveolar macrophage is however 
unknown. Furthermore, in ALI the macrophage may be exposed to a reduced pO2 and 
this may modulate its responses. 
Two key mediators in the development of ALI produced by alveolar macrophages are 
Nitric Oxide (NO) and Tumour Necrosis Factor-α (TNF). There have been studies on 
the effect of varying oxygen levels on the production of NO and TNF in a range of 
macrophage cell lines [200-202] and primary cells [82;83] but the concurrent 
production of both from a murine alveolar macrophage line (MH-S) exposed to severe 
hypoxia has not been studied. In addition, the effects of pharmacological manipulation 
of Hif-1, by a prolyl-hydroxylase inhibitor, on alveolar macrophage responses to 
injurious stimuli have not been reported. CXCL-12 was the first chemokine to be 
shown as being regulated by Hif-1α. It is chemotactic for a range of inflammatory 
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cells and has been shown to have a role in wound healing and renal ischaemic 
responses. It may also have a role in pulmonary inflammatory responses. The in vitro 
synthesis of CXCL-12 has not been described for the MH-S line. 
The hypothesis being considered in this chapter was that “Hif-1 mediates the pro-
inflammatory response to injury by alveolar macrophages”. 
To test this hypothesis the aims of this chapter were to: 
-study the effects of varied oxygen concentrations on NO and TNF production 
by a murine alveolar macrophage cell line  
-study the effect of a prolyl-hydroxylase inhibitor, dimethyloxalylglycine 
(DMOG), on concurrent NO and TNF release 





4.2.1 Establishment of optimal cell density and dose of LPS. 
In order to determine an appropriate cell density to be used an initial experiment was 
performed in a 24 well plate with cells used at 3 different densities. LPS was added at 
1μg/ml to some wells and cells were cultured for 24 hours. The production of nitrite is 































Figure 4-1 Nitrite levels in supernatants from cultured MH-S cells Results from 




On the basis of this experiment it was decided that 2x10
5
cells per well in 1ml of 
medium was a suitable density. This balanced the need for a robustly detectable range 
of nitrite production with using an economical number of cells per well. 
Subsequently an experiment was performed using the established cell density to 
determine a suitable dose of LPS to use. The result is shown in Figure 4-2. 
 
 














































Figure 4-2 Nitrite generation by MH-S cells in response to varying doses of LPS. Results 
from triplicate wells plated at 200,000 cells per well. Triplicate results shown. 
 
On the basis of this experiment and preliminary data which showed an augmented 
response with DMOG (not shown) a dose of 1μg/ml LPS was chosen as the standard 
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dose of LPS used. The production of nitrite and dose of LPS chosen corresponded 
well to other investigators results published in the literature[203]. 
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Finally, to determine an optimal time for measuring nitrite production experiments 
were performed collecting supernatant at 1,2, 6, 24 and 48 hours after addition of LPS 
(Figure 4-3). 
 



















Figure 4-3 Timecourse for Nitrite generation by MH-S Cells. Error bars represent 
Standard Error. Results for triplicate wells shown. 
 
It can be seen that nitrite levels first became easily detectable at 24 hours and 
continued to increase in wells given LPS for up to 48 hours. However, using LDH as 
a measure of cell death it was apparent that by 48 hours there were high levels of cell 
death in wells given LPS (Graph 3-4), approaching 50%. Therefore 24 hours was 
chosen for the remaining experiments. 
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Figure 4-4 Cell death assessed by LDH release in response to LPS. Error bars represent 
Standard Error. Results for triplicate wells shown. 
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4.2.2 Effects of hypoxic culture on MH-S response to LPS 
To test the effect of hypoxic exposure on the response of MH-S cells to LPS it was 
decided to expose the cells to an atmosphere of 0.5% oxygen (5%CO2/94.5%N2), a 
severe level of hypoxia which has been shown to induce Hif-1α protein stability in 
macrophages (Blouin et al [142] used 1%). In addition cells were also studied at 14% 
atmospheric oxygen, corresponding to alveolar levels, to compare the effect of this 
with traditional culture conditions at room air (21% oxygen) which can be viewed as 
hyperoxic. 
























































Figure 4-5 Generation of Nitrite in response to LPS in MH-S cells cultured in varying 
ambient oxygen levels. Error bars represent Standard Error. * p<0.001 compared to 
21% oxygen. **p<0.001 compared to 14% oxygen. Result of 3 separate experiments with 
triplicate wells. 
 
Minimal nitrite was produced by resting cells at all oxygen concentrations. As 
expected cells cultured in room air given LPS generated large amounts of nitrite over 
the 24 hour period. There was no difference in nitrite generation between cells given 
LPS cultured at 21% or 14% (17.37 v17.27 μM p=NS) so all future experiments were 
performed solely with control cells cultured at 21% oxygen. Cells cultured at 0.5% 
oxygen for 24 hours produced significantly less nitrite (3.126+/-0.6 μM v 17.4+/-3.7) 
compared to cells cultured at 21% with LPS.  
TNF levels in supernatant were measured for cells cultured at 21% and 0.5% both in 







































Figure 4-6 TNF release by MH-S cells in response to LPS in Normoxia or hypoxia (0.5% 
Oxygen). Error bars represent Standard Error. *p<0.05 compared to 21% oxygen. 
Result of 3 separate experiments with triplicate wells. 
 
Again as expected resting cells produced minimal levels of TNF (21% 125+/-
42pg/ml) and there was no effect with culture at 0.5%. Exposure to LPS resulted in 
the production of large amounts of TNF again similar to results obtained in a previous 
study [203]. There was no significant effect on TNF production in response to LPS 
when the cells were cultured at 0.5% oxygen (21%+LPS 9630 ± 2098 N=3 v 




4.2.3 Effect of hyperoxic culture on MH-S response to LPS 
Patients with lung injury are treated with supplemental oxygen. It was therefore 
decided to study the effects of 24 hours of hyperoxic exposure on cells. 60% oxygen 
was chosen as an appropriate level of hyperoxia as this represents a clinically 
achievable level of oxygen in spontaneously ventilating patients. 
As can be seen from Figure 4-7 hyperoxic culture had no significant effect on nitrite 
production either in cells at rest or exposed to LPS. 
 
 






































Figure 4-7 Nitrite release by MH-S cells in normoxia or hyperoxia (60% oxygen) in 
response to LPS. Error bars represent Standard Error. Result of 3 separate experiments 






There was similar levels of LDH release in all conditions (figure 4-8) suggesting that 







































Figure 4-8 LDH release by MH-S cells in normoxia and hyperoxia (60% oxygen) in the 
presence or absence of LPS. Result of 3 separate experiments with triplicate wells. 
p>0.05 for all conditions. 
 
 
The expression of TNF in this series of experiments was measured in 2 sets of the 3 
experiments. There was no difference in TNF production between cells grown at 21% 


































Figure 4-9 TNF release by MH-S cells in normoxia or hyperoxia (60%)  in response to 
LPS. Error bars represent Standard Error. Result of 3 separate experiments with 




4.2.4 Reoxygenation rapidly increases nitrite levels in hypoxic culture 
Having shown that hypoxic culture resulted in a reduction in the production of nitrite 
following LPS exposure and that hyperoxic culture had no significant effect on nitrite 
production it was decided to study the effect of a period of hypoxia (18 hours) 
followed by a varied period of reoxygenation. Again 60% oxygen was chosen as the 
reoxygenation atmosphere as it was felt to represent the clinical situation of interest 
where a patient has been unwell for a period of time and is then resuscitated in 
hospital with supranormal levels of oxygen. Control conditions were 21% Oxygen for 
24 hours and addition of LPS to normoxic cells for 24 hours acted as a maximal 
stimulus. 





































































Figure 4-10 Generation of nitrite by MH-S cells exposed to 21% oxygen for 24 hours or 18 hours 
of 0.5% oxygen followed by varying periods of 60% oxygen. Error bars represent Standard 






























































Figure 4-11 Generation of nitrite by MH-S cells exposed to 21% oxygen for 24 hours or 
18 hours of 0.5% oxygen followed by varying periods of 60% oxygen in response to LPS. 
Result of 3 separate experiments with triplicate wells. *p=0.001 compared to 21% 
oxygen plus LPS. 
 
 
It can be seen that cells not exposed to LPS again produced minimal levels of nitrite 
which was not different to cells grown at 21% for 24 hours. Reoxygenation over a 6 
hour period however resulted in a rapid increase in nitrite in the medium with levels 
by 4 and 6 hours not being significantly different from 24 hour 21%+LPS levels. This 
suggests that the lack of NO in cells exposed to LPS and grown at 0.5% oxygen may 
be due to substrate limitation (i.e. nitric oxide synthases are present but unable to 





4.4.4 Inducible Nitric Oxide Synthase expression in MH-S cells 
To further investigate the production of NO by MH-S cells in response to LPS in 
hypoxia the expression of inducible Nitric Oxide Synthase (iNOS) was studied by 
Western blot. Cells were cultured for 24 hours at room air or in 0.5% oxygen in the 
presence or absence of LPS. A representative immunoblot is shown below: 
 
Figure 4-12 Western blot showing increased expression of inducible Nitric oxide 
synthase in the presence of LPS in 21% or 0.5% oxygen Results from 2 separate 
experiments shown. Numbers indicate molecular weight markers. 
 
iNOS is detected as a band at 130kDa. As expected there is minimal expression at 
21% oxygen in the absence of LPS. LPS results in a large increase in protein 
expression after 24 hours culture. Hypoxic culture alone results in a small increase in 
iNOS protein consistent with the reports that iNOS has an HRE as part of its promoter 
sequence. There is a further increase in iNOS protein in cells grown in 0.5%oxygen 
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and LPS. This supports the suggestion that in severe hypoxia NO generation is limited 
by the availability of one of the main substrates, oxygen. 
 
4.4.5 Effect of the Prolyl hydroxylase inhibitor, Dimethyloxalylglycine, on 
MH-S cells 
Some of the effects of hypoxia on the response to LPS in MH-S cells may be 
mediated by an increase in Hif-1α protein as a result of lack of hydroxylation of Hif-
1α and hence its degradation. To investigate this, cells were cultured with DMOG, 
LPS or both. (Figure 4-13). 









































Figure 4-13 generation of nitrite by MH-S cells in the presence of DMOG (1mM) and 
LPS. Error bars represent Standard Error. Result of 3 separate experiments with 






As predicted LPS resulted in increased levels of nitrite compared to medium plus 
vehicle alone. DMOG however also increased the level of nitrite to a similar level as 
LPS while the combination of DMOG plus LPS gave a further significant increase in 
nitrite levels in medium over 24 hours. 
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The production of TNF in these experiments was also measured. (Figure 4-14). 
The addition of DMOG to resting cells had no effect on the production of TNF. 
However, in the presence of LPS DMOG resulted in a significant decrease in the 
release of TNF into the medium. 
 





































Figure 4-14 Release of TNF by MH-S cells in the presence of DMOG (1mM) and LPS. 
Mean result shown. Error bars represent Standard Error. Result of 3 separate 
experiments with triplicate wells. *=p<0.0001. Both LPS treatments were significantly 





To see if this was a specific effect for TNF or the result of a general decrease in 
cytokine secretion the levels of MIP-2, an important chemokine in the recruitment of 





































Figure 4-15 Release of MIP-2 by MH-S cells in the presence of DMOG (1mM) and LPS. 
Mean of three separate experiments with triplicate wells. Error bars represent Standard 
Error. *p<0.05 compared to control condition. 
 
 
There was no effect of DMOG on the LPS induced release of MIP-2 in these 
experiments suggesting a specific effect on TNF synthesis or release. 
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4.4.6 MH-S cells do not express CXCL-12 
It was of interest to define the ability of our macrophage line to express CXCl-12 as it 
is the first Hif-1 regulated chemokine to be described [205] and its expression has 
been described in human macrophages. 
No CXCL-12 was detectable in the supernatant of MH-S cells cultured for 24 hours in 
the presence or absence of LPS. This finding was confirmed by analysis of mRNA 
expression by real time reverse transcription PCR which failed to detect any CXCL-
12 transcription in control cells or cells treated with LPS.  It would therefore seem 
that MH-s cells do not express CXCL-12. 
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4.4.7 DMOG up-regulates several NOS isoforms in MH-S cells. 
The level of iNOS after addition of DMOG was analysed by Western blot (figure 4-
16). These showed that DMOG resulted in a small increase in iNOS expression after 
24 hours culture with DMOG but less than is seen with LPS. The combination of 
DMOG+LPS results in a greater synthesis of iNOS than LPS alone. 
Alveolar macrophages have been reported to express other isoforms of NOS[206] so 
the expression of endothelial NOS (eNOS) (figure 4-17) and neuronal NOS (nNOS) 
(figure 4-18) were investigated. DMOG consistently resulted in an increase in the 
level of eNOS in MH-S cells. There was constitutive expression of eNOS in MH-S 
cells consistent with the report of Miles et al[206] and LPS had little effect on its 
expression. DMOG+LPS expressed more eNOS than LPS alone. Finally the 
expression of nNOS was studied. This was done twice but the results were not 
consistent. A band at 155kDa could be detected in resting cells. One blot showed an 
increase in nNOS with the combination of DMOG+LPS while the other showed no 
significant change in expression due to less protein loading in the treatment lanes.  
This is the first study to look at the expression of all 3 isoforms of NOS in an alveolar 
macrophage line and shows that all eNOS and nNOS are expressed constitutively and 
that both eNOS and iNOS are inducible in response to LPS or DMOG. It would seem 
that the increase in nitrite levels detected after the coculture of cells with DMOG and 






Figure 4-16 Inducible Nitric oxide Synthase expression in MH-S cells exposed to Room 
air (21%), LPS (1mg), DMOG (1mM) or LPS+DMOG for 24 hours. β-actin control 





Figure 4-17 Endothelial Nitric Oxide Synthase expression in MH-S cells exposed to 
Room air (21%), LPS (1mg), DMOG (1mM) or LPS+DMOG for 24 hours. β-actin 
control confirms equal loading. Representative blot of 3 separate experiments. Rat 
endothelial extract was run as a positive control. 
 
 
Figure 4-18 Neuronal Nitric Oxide Synthase expression in MH-S cells exposed to Room 
air (21%), LPS (1mg), DMOG (1mM) or LPS+DMOG for 24 hours. One of 2 
experiments which showed inconsistent results. 
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4.4.8 Up regulation of HO-1 protein by LPS+DMOG 
The down regulation of TNF expression by the combination of LPS+DMOG was 
unexpected following the finding of no effect of hypoxic culture+LPS in MH-S cells. 
One possible explanation for the finding is that DMOG+LPS were a stronger inducer 
of HO-1 expression in these cells. HO-1 has an HRE and has been shown to have anti-
inflammatory effects in macrophages on macrophages acting by the generation of 
carbon monoxide[207]. To investigate this possibility the expression of HO-1 protein 
was studied by western blot (figure 4-19). 
MH-S cells constitutively expressed HO-1 and there was significant increase in the 
band density when cells were cultured with DMOG or concurrent LPS+DMOG 
compared to control, LPS alone or 0.5% oxygen. This raises the possibility that at 
least some of the reduction in TNF expression in these cells is due to the increased 






Figure 4-19 Expression of HO-1 in MH-S cells exposed to Room air (21%), DMOG 
(1mM), LPS (1µg) both DMOG+LPS or hypoxia (0.5% Oxygen). β-actin control 




4.4.9 Expression of Hif-1α protein under varied culture conditions 
All the variables manipulated in the above series of experiments may have at least 
some of their effects through the alteration (increase) of Hif-1α protein. This may 
occur either by increased protein stability (hypoxia, DMOG) as a result of inhibition 
of the PHD enzymes or increased transcription and translation[142;208]. 
 Unfortunately the detection of Hif-1α protein proved to be more problematic than 
anticipated in our murine cell line. Throughout nuclear protein was isolated for 
analysis. Previous success had been achieved with human cells in the CIR[209] using 
a mouse anti-human monoclonal antibody to Hif-1α. In my hands under a range of 
conditions I could detect no protein expression using this antibody. 
Subsequently the ab-1 antibody from Abcam was tried. This resulted in a faint band in 
hypoxic cells at about 95kDa. Discussion with Dr Thorsten Crammer revealed that his 
group had had similar difficulties in detecting Hif-1α protein by Western blot and had 
recommended a polyclonal rabbit anti-human antibody (Cayman Chemicals Cat 
No.10006421).  
A western blot comparing the 3 described antibodies is shown below. The BD 
antibody revealed no detectable band, both ab-1 and the Cayman antibody showed a 
band at 95kDa thought to be Hif-1α. The Cayman ab gave the strongest signal despite 





Figure 4-20 Western blot showing variable ability of Hif-1 antibodies to detect protein. 
Control cells were cultured in room air for 24 hours. DMOG treated cells cultured in the 




To confirm that the 95kDa band was Hif-1α a western blot was performed (figure 4-
20) on nuclear protein obtained from bone marrow derived macrophages obtained 
from Cre Negative (i.e. wild type) and Cre Positive (i.e. Hif-1α deplete)  Hif-1 Cre/lox 
mice cultured under 0.5% oxygen + DMOG to maximally induce Hif-1α. Nuclear 
protein from Cre negative (wild type) and Cre positive (Hif-1 over-expressing) VHL 
bone marrow macrophages cultured at 21% oxygen were also analysed. This 
immunoblot confirms that the Cayman antibody detects Hif-1α as a protein at about 
95kDa (detectable band in WT hypoxic Hif mice and absent in Hif deplete cells; 





Figure 4-21 Western blot using Cayman Antibody to Hif-1 in BMDM from Hif Cre 
Negative and Positive cultured in hypoxia and DMOG (to maximise Hif-1 stabilisation) 
and VHL Cre Negative and Positive animals cultured at 21% (to increase Hif 
destruction). 
 
Subsequently it could be shown that culture with DMOG, LPS, DMOG+LPS and 
0.5%oxygen for 24 hours increased the nuclear levels of Hif-1α in a single 
experiment. Cells exposed to hypoxia seemed to have the greatest increase with 




4.4.10 NF-κB activity in MH-S cells 
In light of the unexpected finding of reduced TNFα production in the presence of 
DMOG the levels of another transcription factor, NF-κB, known to be important in 
the regulation of TNFα production was studied. 
Nuclear protein was collected at 2 and 24 hours and the p65 level measured by Active 
Motif Trans AM assay 
Veh 24 hr 222.73 
DMOG 24Hr 209.12 
Veh + LPS 2 Hr 918.20 
DMOG +LPS 2 Hr 871.46 
Veh 24 hr 302.45 
DMOG 2Hr 203.05 
Veh + LPS 24 Hr 710.68 
DMOG +LPS 24 
Hr  643.08 
 
It can be seen that both LPS and LPS+DMOG increase p65 levels at both 2 and 24 
ours post-stimulus. DMOG alone appears in this cell type to have no effect on p65 





This chapter has been concerned with the response of the MH-S cell line, a well 
characterised murine alveolar macrophage line derived by SV40 viral transformation 
of primary alveolar macrophages obtained from Balb/c mice [143;144] to LPS and the 
manipulation of this response. 
The initial findings of a dose responsive, prolonged generation of NO measured by 
supernatant levels of nitrite are consistent in both quality and quantity with that of 
previous researchers [203] who have employed this cell line. Alveolar macrophages 
are known to be an important source of NO in ALI hence the results of this chapter 
should be of relevance to in vivo events. 
 
4.5.1 Effect of varying ambient oxygen 
Murine macrophages secrete NO in response to LPS alone, unlike human 
macrophages which need a cocktail of stimuli to induce NO production [210]. There 
are three isoforms of NOS; Type I (neuronal); Type II (inducible) and Type III 
(endothelial). Types I and III are constitutively expressed, calcium dependent and 
secrete low levels of NO. Inducible nitric oxide Synthase (iNOS) is a calcium 
independent, high output enzyme which continues to produce NO until the enzyme is 
degraded. Both iNOS [211] and eNOS [212] have been shown to possess an Hypoxia-
response element in their promoter sequence and nNOS has also been shown to be 
regulated by hypoxia[213]. Alveolar macrophages are an important source of NO in 
ALI and thus the potential effects of varied alveolar oxygen as a result of the initial 
insult or subsequent resuscitation need to be understood. 
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Initially three levels of ambient oxygen were studied, 21% (room air), 14% and 0.5%. 
14% was chosen to approximate to normal alveolar pO2 and comparison with room air 
showed no significant difference in NO generation, consistent with the findings of 
others [214]. This allowed us to remove the 14% group from future studies for ease of 
experimental design.  
A major finding was that severe hypoxia reduced the generation of NO in the 
supernatant in response to LPS despite an increased expression of iNOS. This is in 
agreement with other studies using macrophage cell lines derived from other primary 
cells (ANA-1, a C57/Bl6 bone marrow derived macrophage cell line transformed by 
the J2 retrovirus, [211]; Raw 264.7, derived from Balb/c peritoneal macrophages 
transformed by Abelson virus [214;215]. The ability of reoxygenation to rapidly 
increase the supernatant levels of NO suggests that oxygen availability is the rate 
limiting step in the generation of NO in severe hypoxia. This increase in NO 
generation upon reoxygenation has not been shown by previous investigators[202] 
although they used 21% oxygen to reoxygenate and a shorter (2 hour) period, 
suggesting that more rapid delivery of oxygen results in more rapid restoration of NO 
generation. Furthermore, it has been shown in humans in vivo that the rate limiting 
step for the production of NO in lungs is inspired oxygen[216] and that major 
reductions in exhaled NO are not measurable until inspired oxygen is as low as 5%.  
Prolonged hyperoxia had no effect compared to room air on the amount of NO 
generated.  
In agreement with others[211] hypoxia alone had little effect on iNOS protein levels, 
despite the presence of an HRE in the iNOS promoter. Instead, hypoxia seems to act 
as a co-stimulus to increase the levels of iNOS synthesised. This may be a control 
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mechanism to prevent inappropriate synthesis of iNOS in the absence of other 
inflammatory stimuli. 
As expected, LPS resulted in the production of large quantities of TNF by MH-S 
cells. The effect of varying oxygen on TNF production following LPS stimulation in 
the literature is conflicting. Using primary alveolar macrophages from rats Leeper-
Woodford & Detmer [83] found that 1.8% oxygen increased the LPS generated 
release of TNF. VanOtteren et al [82] studying the response of murine primary 
alveolar macrophages suggested that 12 hours of anoxic culture resulted in a small 
statistically not significant increase in TNF mRNA and that 6 hours of anoxia 
followed by 12 hours reoxygenation resulted in a significant increase in TNF protein 
secretion. Others, have found no effect on TNF secretion using BMDM derived[200]) 
or peritoneal derived [201;215] cell lines. Hence the finding in this system that 
varying ambient oxygen does not affect TNF secretion is in keeping with the results 





4.5.2 Effect of DMOG 
DMOG, a prolyl hydroxylase inhibitor, has been shown to increase the expression of 
hypoxia regulated genes in a range of cell types. Its mode of action is thought to be 
through inhibition of the prolyl-hydroxylases, PHD 1-3, leading to stabilisation of 

































Figure 4-22 Mechanism of action of DMOG. The main action is thought to be the 
inhibition of PHD activity. 
 
This is the first study we are aware of where the effect of DMOG on alveolar 
macrophage responses to inflammation has been studied. 
DMOG increases macrophage generation of NO alone and has an additive effect with 
LPS.  Alone, DMOG caused an increase in iNOS protein (although less than LPS 
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alone) and the combination of DMOG and LPS caused a greater expression of iNOS 
than LPS. Hence the additive effect of DMOG and LPS can be explained by a further 
increase in NO generation as a result of increased enzyme levels. However, the 
generation of similar amounts on NO by DMOG alone compared to LPS seems harder 
to explain as, despite an increase in iNOS expression with DMOG the increase is less 
than LPS alone.  
This led to the study of the expression of other isoforms of NOS in the MH-S line. We 
have shown for the first time that MH-S cells express both eNOS and nNOS. eNOS is 
known to have an HRE and we have shown that DMOG alone results in an increase in 
eNOS expression. Whether the observed generation of NO by DMOG treated MH-S 
cells to levels similar to that occurring in response to LPS is due to the combined 
increase in iNOS (high output enzyme) and eNOS (low output enzyme) in DMOG 
treated cells is uncertain and deserves further study.  A possible role for nNOS in the 
generation of NO in response to DMOG could not be confirmed because of 
conflicting results however, nNOS has been shown to be regulated by hypoxia and its 
promoter has potential Hif-1 binding sites[213]. 
A consistent finding was that the generation of TNF in response to LPS was 
significantly reduced by DMOG exposure. This was an unexpected finding in light of 
Peyssonnaux et al’s [218] finding that Hif-1 deplete BMDM generate reduced TNF in 
response to Group A streptococci. However our results are in agreement with recent 
in vivo findings that DMOG reduces TNF release in inflammation [217;219]. In our 
system this would seem to be a specific effect on TNF rather than a non-specific 
inhibition of cytokine release as the release of MIP-2, a potent neutrophil chemokine 
that is the murine equivalent of Il-8 and has been shown to be important in the 
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development of ALI in mice [74;204] was unaffected.  The mechanism for DMOG’s 
reduction in TNF release is unclear. A possible Hif-1 mediated pathway for the 
reduction in TNF release is through induction of HO-1 by DMOG. HO-1 is the rate 
limiting step in the oxidative degradation of heme to CO, iron and bilirubin. HO-1’s 
products have been shown to have anti-inflammatory properties [207;220;221]. Using 
western blot we have shown that MH-S cells express HO-1 and that the combination 
of DMOG and LPS increase the expression of the enzyme to greater levels than 
DMOG or LPS alone. Hence the reduction in TNF release may be mediated by HO-1 
products such as CO acting via a cGMP dependent pathway. The availability of HO 
inhibitors such as mesoporphyrin and HO knockout mice would allow further 
investigation of the possible mechanisms involved. 
An alternative explanation for the alteration in supernatant TNFα levels would be that 
DMOG induces a change in the proportion of membrane bound to soluble TNFα 
[222]. TNFα is produced initially as a 26kDa membrane associated form (mTNFα) 
which is then released as the soluble 17kDa (solTNFα) form by the action of TNFα-
converting enzyme (TACE) [223]. It is known that there is increased expression of 
mTNFα in patients with ARDS [222] and that while solTNFα levels may reflect 
systemic TNF activity it is thought that mTNFα levels may be a better reflection of 
the pulmonary TNF activity. Alveolar macrophages expressing mTNFα may have a 
direct interaction with the alveolar-capillary barrier leading to DAD.  Alternatively 
the action of TACE could be affected by the DMOG. LPS is known to increase the 
levels of TACE in alveolar macrophages [224] and DMOG may have an unexpected 
effect on the synthesis or activity of this enzyme. TNFα ELISAs are thought to 
recognise the solTNFα but can also recognise the receptor bound form [225] which 
may have biological action and can interfere with the recognition of solTNFα. The 
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suppliers of the TNFα ELISA used in this body of work are unable to identify the 
epitope that the capture antibody recognises on the TNFα molecule. Future work 
should study the effects of DMOG on the levels of mTNFα, the release of TNF 





4.5.3 Expression of Transcription factors in MH-S cells 
In this study the measurement of 2 transcription factors was attempted. Determining 
the expression of Hif-1 by MH-S cells proved more difficult than expected from 
review of the literature. Using a rabbit polyclonal antibody we were able to show the 
presence of an oxygen sensitive band at 95kDa. The identity of this band was 
confirmed using BMDM from Hif-1 deleted cells exposed to hypoxia which showed 
reduced staining compared to wild type and normoxic expression of the protein by 
VHL (Hif-1 over-expressing) cells in normoxia. The literature frequently describes 
Hif-1 on western blot as a 120kDa band but these reports are usually from human 
studies [226;227]. Other studies have shown that murine Hif-1[228]  can be detected 
at around 95kDa. In agreement with others work [142;208] LPS resulted in an 
increase in Hif-1 protein at 24 hours. Unfortunately it was not possible to further 
study the kinetics of Hif-1 expression in this model due to time constraints. 
In light of a report that DMOG may affect the activity of components of the NF-κB 
pathway[229] a single experiment was made to study p65, a component of NF-κB 
expression. As expected LPS increased p65 levels but interesting DMOG appeared to 
have no effect in this cell line. However this limited study could not determine any 
effect of DMOG on p65 levels. This needs repeated. The effect of DMOG on NF-κB 
in alveolar macrophages may differ to that shown in intestinal epithelial cells[217] but 
the importance of IκB kinase in macrophage activity [230-232] and its inhibition by 




4.6 Conclusion and further work 
This chapter has been concerned with the response of an alveolar macrophage cell line 
to stimuli relevant to lung injury (LPS and hypoxia/hyperoxia) and the effect of a 
pharmacological agent (DMOG) on some of these responses. 
This study has shown that MH-S cells express all the isoforms of NO Synthase and 
that they have differing responses to LPS. It has also confirmed that ambient oxygen 
is a rate determining feature of NO synthesis by alveolar macrophages. 
Furthermore it has shown that DMOG increases the expression of NO (an anti-
bacterial agent) while reducing the secretion of TNF, an important pro-inflammatory 
cytokine. This raises the possibility that administration of DMOG may enhance 
bacterial killing via NO generation while reducing other potentially deleterious 
features of the inflammatory response induced by TNF. This will be examined further 
in chapter 6. 
In order to clarify the role of the different isoforms of NO Synthase on NO generation 
in response to DMOG the use of BMDM from knockout mice would be invaluable. 
Unfortunately they were not available to us during this project but the response of 
nNOS, iNOS and eNOS knockout cells to DMOG would be interesting. Furthermore 
the use of HO-1 knockout cells to determine the relevance of the observed increase in 
HO-1 expression in response to DMOG and its potential effect on LPS induced TNF 
generation would be important. As already discussed the measurement of mTNFα and 
TACE activity would help clarify the mechanism for the reduction in TNFα levels in 
medium following LPS exposure. 
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Now that the tools are available to study the levels of Hif-1 protein in MH-S cells it 
would be valuable to study these in more detail over varying durations and doses of 
LPS exposure. As discussed above the role of the NF-κB pathway in mediating the 
effects of DMOG requires investigation. The availability of techniques such as short-
interfering RNA would allow the exploration of the importance of Hif-1α and NF-κB 
mediated effects to be explored by using DMOG to increase the level of the 
transcription factor of interest while blocking the activity of the other. The interaction 
between DMOG and Hif should also be explored using the availability of Hif-1α [89]  














Endotoxin induced lung injury in 





The use of genetically modified animals, particularly mice, has proven to be a 
powerful tool in biological science allowing researchers to understand the role of 
specific molecules in the generation of biological responses in vivo. It is possible to 
alter the mouse genome with nucleotide precision allowing the study of single gene 
function in intact animals and in models of human health and disease. 
Hif-1α is an important gene in embryonic development. A Hif-1α knockout mouse has 
been generated but it is a lethal mutation with embryonic death occurring by day E11 
as a result of severe cardiovascular and neural tube defects [94] . This has lead to 
other approaches to study the effect of Hif-1α expression in adult animals. Using the 
Cre/lox system [234] Randal Johnson’s group at the University of California have 
been able to generate mice with a targeted deletion of Hif-1α in myeloid cells [89]. 
They have previously reported the generation of a loxP-flanked (floxed) allele of Hif-
1α in mouse embryonic fibroblasts [103] which in the presence of cre recombinase 
results in the excision of a segment of exon 2 which encodes the helix-loop-helix 
motif which is essential for Hif dimerisation with Hif-1β and subsequent 
transcriptional activity. Targeted deletions of Hif-1α mice were created by crossing 
this floxed allele into the LysMCre mouse [235]. The LysMCre mouse expresses the 
enzyme Cre recombinase under the control of the Lysozyme M promoter. This results 
in the expression of Cre in all myeloid cells. This cre expression then results in the 
excision of the floxed segment of Hif-1α and the generation of myeloid cells which 
are unable to generate functional Hif-1α (Fig 5-1). This animal is therefore a powerful 
tool with which to explore the role of Hif-1α in the generation of inflammatory injury. 
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Professor Johnson supplied our group with breeding pairs of the Hif-1α knockout 
mouse with which we were able to generate our own breeding colony. 
The hypothesis tested in this chapter was that Hif-1α myeloid cell knockout mice 
would have attenuated lung injury in response to endotoxin. 
The aims of this chapter were to: 
 -confirm the genotype of the breeding colony 
 -establish the expression of cre in alveolar macrophages 
-confirm the action of cre in alveolar macrophages and establish the deletion      
efficiency of the system 
 -study the role of myeloid cell Hif-1α in response to intratracheal LPS 





Figure 5-1Summary of the mechanism of the cre/lox system. The gene of interest is 
flanked on both sides “floxed” by the bacteriophage sequence loxP (locus of X-over P1). 
Under the control of a specific promoter element (in this works case Lysozyme M) the 
enzyme Cre (cyclization recombination) is expressed in the cell of interest (here the 
myeoloid cell line). The action of cre is to excise the floxed sequence and hence prevent 




5.2.1 Confirmation of presence of floxed alleles 
The Hif-1α conditional deleted mice (referred to hereon as Hif knockout [KO]) were 
maintained in the Edinburgh University Biomedical Research Resources animal 
facility at Little France. Genotyping for cre expression was performed in house by 
BRR staff by real time PCR with heme oxygenase 1 run as a positive control. Ear clip 
samples were used to provide DA which was extracted by standard methods. 
Using sequences provided by Prof. Johnson the presence of floxed alleles was 
confirmed by PCR and gel electrophoresis (Fig 5-2)     
     
Figure 5-2 Genomic PCR confirming presence of loxP sites in Hif KO mice. –
ve=negative control sample(water) SH29-32 are Hif KO animals, Normal 1 and 2 are 





5.2.2 Bone Marrow Derived Macrophages express Cre recombinase 
The cre lox system employed depends on the expression of cre at some point of the 
cell cycle (controlled in this case by the Lysosyme M promoter). In order to support 
the findings of Cramer et al [89] that bone marrow derived circulating inflammatory 
cells are Hif-1α knocked depleted in this strain the expression of the cre recombinase 




Figure 5-3 Western blot of Cytoplasmic (Cyto) and Nuclear (Nuc) Extracts from Cre 
Positive (Pos) and Negative (Neg) Hif mice confirming expression of cre in nucleus of 






5.2.3 Alveolar macrophages express cre recombinase in the Hif mouse. 
To confirm the expression of the cre recombinase enzyme in alveolar macrophages of 
cre positive animals, lung sections from floxed Hif mice which were known by 
genotyping to be Cre positive and negative were stained for cre by 
immunohistochemistry. This confirmed the nuclear expression of cre in alveolar 





Figure 5-4 Immunohistochemical stain of Lung sections from Cre Negative and Positive 




     
5.2.4 Deletion efficiency of Hif-1α in Mouse Alveolar Macrophages. 
Cramer et al [89] have shown that the cre/lox system results in a high degree of 
deletion of the targeted Hif-1α exon in peritoneal macrophages and neutrophils but the 
deletion efficiency in other myeloid cells is unknown. Alveolar macrophages were 
harvested from Cre negative (wild type Hif-1α expression) and Cre positive (KO) 
animals. Genomic DNA was extracted from these cells and stored.  Using quantative 
PCR the deletion efficiency in alveolar macrophages was shown to be high. HO-1 
expression was used as the reference gene against which Hif-1 levels were expressed. 

















Figure 5-5 Genomic amount of Hif-1 compared to HO-1 in wild type (WT, cre negative)  
and knockout (KO, cre positive) animals 5 animals per group. Error bar represent SE. 
 
The deletion efficiency in alveolar macrophages is higher than in BMDM and 
neutrophils as reported by Cramer et al [89]. This likely reflects the nature of the 
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alveolar macrophage in that it is a mature terminally differentiated cell which has had 
a prolonged period of growth and differentiation in which cre can be expressed and 
act on the floxed allele. 
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5.2.5 Wild type and Hif-1α myeloid knock-out mice have similar alveolar 
lavage cell populations following intratracheal saline. 
A small number of wild type and KO mice were given intratracheal saline and then 
underwent BAL at 6 hours.  The results are shown in Figure 5-5. 
Both WT and KO mice had similar macrophage predominant populations with similar 
BAL protein levels suggesting that the Hif-1α myeloid knockout does not affect 



















































































BAL results from WT and KO mice
6 hours after IT Saline
 
 
Figure 5-6 Bronchoalveolar lavage results from WT or KO mice given intratracheal 
saline. Each data point represents an individual animal. Bar equals mean value. No 




5.2.6 Hif-1α myeloid Knock-out mice develop pulmonary inflammation in 
response to intratracheal LPS. 
Subsequent to the above experiment BALs were obtained from 3 groups of KO mice: 
naïve, unstimulated animals; animals that had received intratracheal saline 6 hours 
prior to sacrifice and animals that had received intratracheal LPS 6 hours previously. 
The cell counts and BAL protein levels are shown in Figure 5-6. 
The results confirm that naïve KO mice have an alveolar cell population that is 
predominantly composed of alveolar macrophages. At the 6 hour timepoint there is 
also little effect from intratracheal saline. The alveolar population remains 
predominantly macrophage and there is no evidence of an alteration in alveolar 
capillary integrity reflected by the lack of a change in BAL protein levels.  
Intratracheal LPS however, results in a neutrophilic alveolitis with an increase in total 
cell number, a sHift to a neutrophil rich lavage population and evidence of alveolar 
















































































































BAL Results from KO mice
unchallenged (naive) or 6 hours after
PBS or LPS
 
Figure 5-7 Bronchoalveolar lavage results from unchallenged mice or mice given either 
saline or LPS intratracheally. Each data point represents an individual animal. Bar 




5.2.7 Hif-1α myeloid knockout mice develop a similar pattern of Acute 
Lung injury following intratracheal LPS to wild type mice. 
Having shown that KO mice can develop ALI we then compared the response to i.t. 
LPS at various timepoints. Timepoints ranging from 2 hours to 5 days were studied to 
allow full characterisation of the response to LPS which has been shown to have 
differing peaks for inflammatory cell infiltration and alveolar-capillary damage 
[187;194]. The timepoints chosen were 2 hours; 6 hours; 24 hours; 48 hours and 5 
days after i.t. instillation of LPS. The data are summarised in figure 5-7 and the results 





















































BAL results after intratracheal LPS
 
Figure 5-8 Summary data from animals given intratracheal LPS and sacrificed at 2, 6, 
24, 48 and 120 hours. Each point represents mean result. Error bars denote standard 




Total cell number and neutrophil number are increased by LPS instillation. Both peak 
at 48 hours after insult. BAL protein also peaks at 48hours following LPS. Comparing 
WT and KO mice it can be seen that the results are similar, both resulting in an 
intense neutrophilic alveolitis with an increase in BAL protein representing alveolar-
capillary damage. 
At 2 hours after LPS instillation there are fewer neutrophils in the KO BAL than WT. 
2 hours is the earliest time at which one would expect to see PMN in the BAL as a 
result of LPS instillation [187] and our findings suggest that KO PMN are slower in 
their migration to the airspace than WT. This difference however is lost by 6 hours 
confirming that PMN from KO mice are able to migrate to sites of injury [218]. The 
ability of these migrated PMNs to cause damage is confirmed by the increase in BAL 
protein seen during the course of the study. 
An interesting observation is that KO BAL protein remains elevated at 5 days 
following the insult while the WT BAL protein level has dropped significantly (48 











































































BAL results from WT and KO mice
2hours after IT LPS
 
 
Figure 5-9 Bronchoalveolar lavage results from WT and KO animals given 50 μg 
intratracheal LPS and sacrificed at 2 hours post-instillation. Each data point represents 

























































































BAL results from WT and KO mice
6 hours after IT LPS
 
 
Figure 5-10 Bronchoalveolar lavage results from WT and KO animals given 50 μg 
intratracheal LPS and sacrificed at 6 hours post-instillation. Each data point represents 
an individual animal. Bar equals mean value. Groups compared by Mann-Whitney test. 

























































































BAL results from WT and KO mice
24 hours after IT LPS
 
Figure 5-11 Bronchoalveolar lavage results from WT and KO animals given 50 μg 
intratracheal LPS and sacrificed at 24 hours post-instillation. Each data point 
represents an individual animal. Bar equals mean value. Groups compared by Mann-

























































































BAL results from WT and KO mice
48 hours after IT LPS
 
Figure 5-12 Bronchoalveolar lavage results from WT and KO animals given 50 μg 
intratracheal LPS and sacrificed at 48 hours post-instillation. Each data point 
represents an individual animal. Bar equals mean value. Groups compared by Mann-

























































































BAL results from WT and KO mice
5days after IT LPS
 
Figure 5-13 Bronchoalveolar lavage results from WT and KO animals given 50 μg 
intratracheal LPS and sacrificed at 120 hours (5 days) post-instillation. Each data point 




The overall similarity in the severity of the injury sustained by WT and KO mice is 
reflected in the change in percent body weight over the 5 day course of one 
experiment (Fig5-13).  
 
Long term weights after IT LPS























Figure 5-14 Change in body weight over 5 days following instillation of 50 μg 
intratracheal LPS. Error bars denote standard error. 
 
This shows that the nadir of bodyweight is reached by day 3 and there is a subsequent 






5.2.8 BAL release of TNFα is not impaired in Hif-1α myeloid deficient 
animals  
TNFα is known to be a potent neutrophil chemoattractant and its elevation in BAL 
fluid is thought to be important in the localisation of neutrophils to the alveolar space 
in lung injury. The release of TNFα in response to intratracheal LPS was therefore 
studied (5-14). There was no significant difference between WT and KO animals 
although the levels at 2 hour level in WT animals was 50% higher than in KO 
animals. 
 














































Figure 5-15 Bronchoalveolar lavage TNF from WT and KO animals given 50 μg 
intratracheal LPS for the time points shown. Each point is mean value. Error bars 





5.2.9 Hif-1α myeloid deficient animals show reduced pulmonary 
nitrosylation in response to LPS. 
Quantitatively the response to intratracheal LPS is similar in WT and KO mice. 
However it is known that the bactericidal effectiveness of KO myeloid cells is 
reduced even though the inflammatory influx seen may be similar [218]. Since the 
generation of NO is thought to have an important role in the bactericidal ability of 
myeloid cells and in the development of ALI the degree of protein nitrosylation (a 
marker of NO mediated tissue damage) was assessed by immunohistochemistry [236]. 
IHC showed that there was greater staining of pulmonary tissue in WT than KO 








Figure 5-16 Nitrotyrosine Immunohistochemistry of lungs from Hif WT and KO 
animals showing reduced protein nitrosylation  at both 24 hours and 5 days in KO 
animals after LPS instillation. A- WT 24hours post LPS. B-KO 24 hours post LPS.       





It was not possible to measure reactive nitrogen species directly in BAL fluid due to 
the presence of haemoglobin in some lavages [237] resulting from alveolar 
haemorrhage [192]. However, the presence of nitrosylated proteins is accepted as an 
indicator of reactive nitrogen generation in studies of ALI [238]. 
 
5.2.10 Maximal Pulmonary Hypoxia is seen at 5 days 
Pimonidazole is a compound which binds to hypoxic proteins irreversibly and can 
therefore be used as a marker of tissue hypoxia by detecting it using 
immunohistochemistry using a commercially available kit. Using this method the 
development of tissue hypoxia was studied in lungs instilled with LPS in animals 
exposed to LPS for 24 or 120 hours. This experiment showed that there was minimal 
tissue hypoxia at 24 hours post-instillation but that by 5 days there were multiple 




Figure 5-17 Immunohistochemical straining for Pimonidazole in lungs from Control (A), 
24 hours IT LPS (B) or 120hours IT LPS (C)showing increased staining centred on 
inflammatory cells at day 5. Section D is kidney confirming the ability of Pimonidazole 
to discriminate normoxic tissue (Glomeruli) from hypoxic (renal tubules). Magnification 





5.2.11 Hif-1α depleted Bone Marrow Derived Macrophages produce less 
Nitric oxide in response to Endotoxin 
Bone Marrow Derived Macrophages (BMDM) were cultured by established 
techniques and then exposed to LPS. Neither unstimulated WT nor KO BMDM 
generated significant quantities of nitrite over the study period. In response to LPS 
both WT and KO BMDM generated increased amounts of nitrite but KO BMDM 














































Figure 5-18 Nitrite release from Bone Marrow Derived Macrophages from WT or KO 
animals exposed to Saline or 1μg LPS for 24 hours. Each point represents mean result of 
triplicate wells from one animal. Bar at mean value. Statistical difference shown by 
MannWhitney test. 
To confirm these results a Western blot was performed to study the generation of 
iNOS protein in response to LPS. It can be seen that the amount of iNOS present in 
LPS stimulated Hif-1α KO BMDM is greatly reduced compared to WT. 
                                                   
Figure 5-19 iNOS protein from KO or WT animals BMDM after LPS stimulation. 
 
iNOS band  present in WT but not KO 
animals after LPS stimulation 
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This confirms the key role of myeloid Hif-1α in the generation of reactive nitrogen 
species in response to bacterial infection. 
The response to bacterial infection is controlled by the release of cytokines from 
myeloid cell, one of which TNFα, is thought to have a central role in the generation of 
the immune response. To determine whether this regulatory function of myeloid cells 
is altered in Hif-deficient cells BMDM from WT and KO animals were exposed to 




TNF production over 48 hours
















Figure 5-20 Release of TNF in response to 1μg LPS by WT or KO BMDM. Mean result 
of 3-7 animals per time point shown. Error bars denote standard error. P values 




At 6 hours WT BMDM had released significantly more TNFα than WT. However 
there was no difference at 1 hour and this effect was lost at 24 and 48 hours. 
 
5.2.12 VHL mice show no difference in response to LPS after 5 days. 
Some mice, which over express myeloid Hif-1α (known as VHL) due to a conditional 
depletion of the von Hippel Lindau protein, became available towards the end of the 
project. An experiment was performed in which VHL mice and their WT littermates 
were exposed to intratracheal LPS and then underwent BAL at 5 days (figures 5-18   






























































































BAL results from WT and VHL mice 5 days
after IT LPS
 
Figure 5-21 Bronchoalveolar lavage results from WT and Hif-1 over-expressing (VHL) 
animals exposed to 50μg intratracheal LPS for 120 hours. Each point represents an 
indivaidual animal, bar is mean result. No difference between wild type and knockout 





























Figure 5-22 Percent weight change in WT and VHL animals exposed to 50μg 
intratracheal LPS over 5 days. Mean values shown. Error bars denote standard error. 
 
It can be seen that over the 5 day period both groups of animals had a similar change 
in body weight and that BAL performed on day 5 gave similar results. This supports 
the observations in the Hif-1α deplete mice that they have a similar systemic response 




This chapter has been concerned with the characterisation of the Hif-1α myeloid cell 
conditional knockout mouse gifted from Prof. R Johnson and exploring its response to 
intratracheal LPS as a model of Acute Lung Injury. 
The presence of the floxed alleles in the genomic DNA of the animals was confirmed 
and the efficiency of the process was shown to be high in terminally differentiated 
alveolar macrophages. The deletion efficiency is slightly higher in our alveolar 
macrophage population than was reported by Cramer et al [89] in a population of 
peritoneal macrophages. Macrophages are an heterogeneous population [239;240] of 
cells. By immunohistochemistry we have shown that alveolar macrophages in these 
animals continue to express the Cyclization recombination (Cre) gene in their nuclei. 
Persistent expression of this enzyme allows for the deletion of the floxed segment of 
target gene occurring at any stage of the cell’s lifecycle once Lysozyme M is 
expressed. The expression of Lysozyme M is progressively turned on during myeloid 
cell development [241]. Therefore it could be hypothesised that more mature cells 
have a greater likelihood of having the floxed segment deleted as they have expressed 
Cre for longer and therefore there is a greater likelihood that the Cre enzyme has acted 
on the floxed segment. Overall the deletion of the Hif-1α target sequence is highly 
efficient in this animal. The use of a cell specific promoter is a relatively new 
approach to studying the effect of a specific cell population. Previous work has used 
liposomal clodronate [242] to deplete the alveolar macrophage population. However, 
this approach does not result in a 100% depletion of the original population, does not 
affect parenchymal cell and most importantly in this field generates a pulmonary 
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inflammatory response [76;243-245]. Therefore the hope of using cell specific 
transgenic animals is that these confounders can be avoided. 
Following the confirmation of the genetic mutation in the animals it has been shown 
that the wild type and knock out littermates have similar bronchoalveolar cell 
populations following saline instillation. This confirms the findings of Cramer et al 
[89] and Peysonneaux et al [218] that the composition of the resting tissue populations 
of inflammatory cells are not affected in this strain of mouse. It is appreciated that the 
activity of Hif-1α in these animals is reduced in all cells of the myeloid lineage 
[89;227]. However, there is no absolutely specific macrophage promoter available 
that would allow this problem to be circumvented. It is possible, having depleted the 
mouse’s own neutrophil population (e.g. by using anti-GR1 antibodies), to transfuse 
mice with neutrophils harvested from the bone marrow [246-248] of donor animals. 
Similarly it is possible to transfer macrophages from one animal to another. It would 
therefore be possible, if a significant effect on injury or repair was seen in the Hif-1α 
knockout animals, to try and tease out the importance of each myeloid cell type by the 
adoptive transfer of either wild-type neutrophils [248] or macrophages[249] to 
knockout animals. However in the data presented in this work the effect of Hif-1α 
deletion appears to be minimal in the development and progression of ALI. 
Subsequently in an experiment only using KO animals it was shown that KO animals 
are able to generate an inflammatory response in response to intratracheal LPS that is 
not seen following intratracheal saline when compared to unchallenged mice. 
The main aim of this chapter was to study the response of Hif-1α KO mice and their 
WT littermates to intratracheal LPS. Over a range of time points we have shown that 
both WT and KO animals develop an intense neutrophilic alveolitis in response to i.t. 
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LPS. The response peaks around 48 hours after challenge and is beginning to resolve 
by day 5 with a reduction in PMN number and increase in animal body weight. 
The results of BAL analysis from WT and KO animals are similar at most timepoints 
with 2 notable exceptions. At 2 hours after challenge there are fewer PMN in the BAL 
of KO animals than WT (KO 7485 ± 925.7 N=4 v WT 12410 ± 1231 N=4 p=0.0186). 
This difference is lost by 6 hours however, and the severity of neutrophil 
inflammation is similar at all subsequent timepoints studied. Cramer et al reported that 
these mice showed deficient inflammatory responses to both topically applied SDS 
and in a model of passively induced arthritis. However, similar to our findings 
Peyssonnaux et al [218] from the same group found that the severity of the 
inflammatory cell response to a skin infection model did not differ between WT and 
KO animals. They hypothesised that the stimulus to neutrophil migration induced by 
bacterial infection was such that it overcame the contribution to migration that Hif-1α 
appeared to play in their earlier study. Hif-1α is central to the generation of ATP in 
myeloid cells and our results would suggest that the energy requiring migration of 
neutrophils is impaired in these animals resulting in slower but still effective 
localisation to inflammatory stimuli. In order to further investigate this finding it 
would be of value to study the inflammatory response at an even earlier timepoint 
(30mins to 1 hour) to see if the difference persists. In addition the ability of KO BM 
derived PMN to migrate in response to classical chemotactic stimuli should be 
assessed using modified Boyden chambers. 
The other difference seen is a 5 days where by this stage the BAL protein level of WT 
animals is staring to fall while in KO animals it remains elevated (WT 615.6 ± 79.51 
N=7 v KO 1106 ± 159.9 N=7, p=0.0178). The reason for this difference is unclear but 
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suggests that Hif-1α may play a role in limiting responses to inflammatory insults, 
turning off injury at the time when pulmonary hypoxia as assessed by Pimonidazole 
binding is greatest in this series of experiments. The identification of areas of hypoxic 
pulmonary tissue is important here as it is not widely appreciated that the abnormal, 
injured lung can have areas of hypoxia as a result of impaired ventilation. It is 
recognised in thoracic surgery that pulmonary ischaemia occurring as a result of loss 
of ventilation and perfusion of the collapsed lung [51;53;54] is an important stimulus 
to injury. However, areas of regional collapse and consolidation seen in the critically 
ill [8] are also likely to result in hypoxic tissue, even though the fraction of inspired 
oxygen may approach 1.0.  
Hif-1α has been shown to have anti-inflammatory effects in T-lymphocytes [250] 
while in animal models of colitis increasing Hif-1α levels pharmacologically has been 
shown to be beneficial [217;219] although the mechanisms are unclear. Furthermore it 
has been shown that oxygen inhibits tissue protection in ALI and exacerbates tissue 
injury [251] while hypoxia for 48 hours was protective (if the animal survived the 
initial hypoxic exposure). This was proposed to be due to the effects of oxygenation 
on adenosine mediated tissue protection. Adenosine generated in the protective 
responses requires the glycolytic generation of ATP the key enzymes for which are 
Hif-1α regulated. Therefore Hif-1 may have a role in the resolution of lung injury that 
was not expected from initial studies. An important off switch of inflammation, the 
release of adenosine acting on the A2A Receptor, modulated by Hif-1α regulated 
production of up-stream mediators, may be impaired resulting in prolonged 
inflammatory damage.  
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Following the resolution of injury over a more prolonged period, to complete 
restoration of normal pulmonary cell populations would support this hypothesis. 
Furthermore this observation raises the possibility of a protective effect from Hif-1 
expression in other, more chronic forms of lung injury, such as interstitial fibrosis, 
which could be tested using the well established bleomycin model of murine lung 
fibrosis. The use of specific A2AR agonists such as CGS 21680 which are 
commercially available to restore the reparative process in KO animals would confirm 
the role of Hif-1 mediated adenosine generation in these animals. 
Reactive nitrogen species have been suggested to play a role in the generation of ALI. 
Nitric oxide Synthase II (inducible nitric oxide [iNOS]) is Hif-1α regulated. Using 
immunohistochemistry we have shown that the generation of nitrosylated proteins in 
the lungs of the KO mice is reduced. Further using harvested BMDM we have shown 
that the lack of generation of nitric oxide in these animals is due to the expected lack 
of induction of iNOS [218]. In agreement with Peyssonnaux et al [218] we also found 
that the generation of TNF was reduced in KO BMDM although this difference was 
only seen at 6 hours after LPS exposure. Again, as in chapter 4, it is not known if 
there is any difference between solTNFα and mTNFα expression in this system. The 
difference in TNFα in medium at 6 hours could be the result of reduced activity of 
TACE. It could therefore be hypothesised that although generation of TNFα might not 
be altered by Hif-1α deficiency the reduced medium release may be explained by 
reduced cleavage of the 26kDa form [222]. However, it should be noted that there 
would not appear to be a biological effect of this potential system in the model of ALI 
as cell infiltration and BAL protein at 6, 24 and 48 hours are unaffected. 
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The late availability of mice over-expressing Hif (VHL mice) meant that only a single 
experiment could be performed using them. The over-expression of Hif did not 
generate a more severe inflammatory response in these animals measured by change 
in body weight. BAL at 5 days showed similar inflammatory cell profiles between 





5.4 Future work 
This chapter has shown that the acute inflammatory response to intratracheal LPS is 
not significantly dependent on myeloid cell Hif-1α. Presumably other mediators such 
as NF-κB and AP-1 are more central to the response. However the data has raised the 
possibility that Hif-1α has a role in the down regulation of the generated response and 
studying the later stages of the repair process would be valuable. Further if Hif-1α has 
a role in the inhibition of inflammatory responses then assessing the role of myeloid 















Manipulation of Endotoxin induced 







Results discussed in the preceding chapter suggest that in the generation of acute lung 
injury manipulation of myeloid cell Hif-1α seems to have minimal effect on the 
quantity of the response although the quality of the response is changed.  
Studies have shown that the pharmacological manipulation of Hif-1α in isolated cells 
[252]or in whole animals [217;219;253] can alter the response to insults. Furthermore 
the manipulation of downstream components of Hif-1 controlled pathways can alter 
the response to inflammatory insults [221;254]. 
Dimethyloxalylglycine (DMOG) is an inhibitor of prolyl hydroxylases, key enzymes 
in the control of Hif-1α metabolism [120]. DMOG and other PHD inhibitors given 
systemically can act as a preconditioner to hypoxic challenge, increasing the tolerance 
of animals to hypoxia [253]. Recently in models of detergent induced colitis two 
separate groups of investigators have shown that the systemic administration of PHD 
inhibitors can reduce the severity of the inflammatory injury [217;219]. Both groups 
used a dosing schedule comprising several treatments with a PHD inhibitor before and 
after administration of the insult. Based on our experiences with DMOG in vitro and 
our interest in the possible manipulation of the response to pulmonary inflammatory 
insults we undertook a study of the effect of local PHD inhibition on the pulmonary 
response to endotoxin. 
Because of the unexpected nature of the insult in ALI it was decided that pre-
treatment of the animals would not give clinically useful information. It was therefore 
decided to administer the DMOG simultaneously with the noxious agent, endotoxin. 
Furthermore it was decided to administer the DMOG intratracheally in order to allow 
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us to study the pulmonary response to the agent and minimise its systemic effects. 
This provides a clinically useful scenario where the administration of agents (e.g. 
Nitric oxide) via the endotracheal tube to patients with ALI has been shown to 
modulate the inflammatory response. Furthermore simultaneous administration 
required the animal to receive only one dose of anaesthetic to allow i.t. dosing. A dose 
of 8mg of DMOG was chosen as this reflects the dose used by other groups in the 
literature [217]. For these experiments the DMOG was dissolved in Phosphate 
buffered saline to avoid any effect from vehicles. 
The hypothesis under investigation here was that manipulation of Hif-1 by the use of 
intratracheal DMOG would alter the response to intratracheal endotoxin. 
The aim of this chapter was to use the previously described model of pulmonary 
inflammation generated by intratracheal endotoxin to study the effect of simultaneous 






6.2.1 Simultaneous DMOG and LPS does not reduce neutrophil 
infiltration in ALI. 
C57/Bl6 mice were anaesthetised and either exposed to i.t. LPS or LPS and DMOG. 
Animals were allowed to recover for 24 hours before sacrifice and BAL. 
Both groups of animals lost approximately 15% of their body weight following dosing 


































Figure 6-1 Change in body weight in animals exposed to intratracheal LPS or 
concurrent LPS and DMOG. 
 




































































































BAL results from mice given intratracheal LPS
or DMOG+LPS
 
Figure 6-2 Bronchoalveolar lavage results from animals exposed to intratracheal LPS or 




As expected the administration of i.t. LPS resulted in an intense neutrophilic 
alveolitis. The simultaneous administration of DMOG at a dose known to 
systemically inhibit PHDs and therefore increase Hif levels did not alter the 
neutrophil influx nor the damage to the alveolar capillary integrity, evidenced by the 
similarity in BAL protein levels. The number of macrophages in the BAL of animals 
given DMOG + LPS was significantly reduced compared to that in LPS treated 
animals alone but the significance of this result is unclear. 
 
6.2.2 Local administration of DMOG increases iNOS expression in BAL 
cells. 
In the previous chapter it was shown that the quality of the inflammatory response 
was different in animals with reduced myeloid Hif-1α expression, specifically the 
reduction in iNOS expression.  
It was decided to study the generation of iNOS by the alveolar infiltrate. To do this 
the cells obtained from BAL were counted and the remaining cells were then lysed 
and their cellular protein was collected. Aliquots of cytoplasmic protein were then 









It can be seen that in the cytoplasmic extract from the dual treated cells there is an 
increase in the expression of iNOS protein. β-actin confirmed similar loading of the 
gel. 
Unfortunately as previous discussed it was not possible to measure BAL nitrite levels 






Figure 6-3 Western blot showing expression of iNOS protein in alveolar cells from 
animals treated with intratracheal LPS or concurrent LPS+DMOG 
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6.2.3 Increased Nitrotyrosine staining in DMOG+LPS treated animals. 
As a surrogate for reactive nitrogen species levels the pattern of protein nitrosylation 
in the lungs of animals treated with LPS alone or LPS+DMOG was studied by 
immunohistochemistry. 
As expected from the result of the iNOS Western blot lungs from animals treated with 
both LPS and DMOG showed increased deposition of nitrosylated protein compared 






Figure 6-4 Nitrotyrosine immunohistochemical stain in animals exposed to intratracheal 
LPS (A) or LPS+DMOG (B and C). x200. Graticule=100µm. 
 
LPS treated animals showed deposition of nitrosylated proteins on some alveolar 
walls and also inflammatory cells. In the animals treated with DMOG+LPS there was 
more intense staining on inflammatory cells. 
These results again suggest, in a similar pattern to the myeloid deplete animals that 
although the quantity of inflammatory infiltrate is not affected by manipulating Hif 





The recent availability of compounds which can pharmacologically manipulate the 
Hif-1 pathway raises the potential for their clinical use in modulating inflammatory 
responses. Dimethyloxalylglycine is a prolyl hydroxylase inhibitor which has been 
shown to have beneficial effects when given to a murine model of Inflammatory 
Bowel Disease [217]. Similar results were found by an independent group using a 
related compound [219] in another model of murine colitis. 
In work previously described here, DMOG was shown to increase the generation of 
Nitric oxide in response to LPS while the release of TNFα was reduced from murine 
alveolar macrophages. Furthermore using the Hif-1α myeloid deplete animals it was 
shown that the nature of the inflammatory response to intratracheal LPS was altered in 
these animals. It was therefore decided to investigate the effect of DMOG 
administration on the pulmonary inflammatory response to LPS. In order to generate 
clinically useful information it was decided to administer a single dose of DMOG at 
the same time as the insult representing as near as possible the original clinical 
scenario this project was interested in of a critically ill patients and the early 
resuscitation/treatment phase. Furthermore the DMOG was administered 
intratracheally to minimise any systemic effects. The DMOG given here will therefore 
have actions on the resident alveolar epithelium, alveolar macrophages and recruited 
inflammatory cells.  
The single dose of DMOG had no effect on the magnitude of the neutrophilic 
infiltrate generated by the LPS. Similarly there was no difference in the degree of 
BAL protein between LPS and LPS+DMOG. This is a significant clinical finding as 
the DMOG could be expected to increase epithelial Vascular Endothelial Growth 
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Factor, a Hif mediated transcription factor which may increase alveolar permeability 
(although prolonged dosing did not lead to an increase in colonic permeability in the 
models of colitis [219]). As predicted by in vivo data the DMOG increased the levels 
of iNOS protein in inflammatory cells measured by Western blotting and there was an 
increase in the generation of nitrosylated proteins seen by immunohistochemistry. 
The data here raises the possibility that the administration of DMOG near to an 
infective insult may be beneficial as there would appear to be little effect on the 
recruitment of inflammatory cells, there is no gross deleterious effect on the alveolar 
epithelial-capillary integrity but there is an increase in the ability of the inflammatory 
cells to generate a bactericidal response measured by reactive nitrogen species.  
There are two future areas of research based on the data. First it would be valuable to 
study the effect of delayed administration of DMOG to the ALI response. Cummins et 
al [217] in their model of colitis found that DMOG increased the repair following 
insult removal and the possibility of a therapeutic option for ALI is an exciting one. 
Secondly the possible beneficial of DMOG in an infective pulmonary insult deserves 
investigation. The results above raise the possibility that administration of DMOG to a 
model of pneumonia may result in an increase in bacterial killing as a result of 


















7 Discussion and Conclusion 
 
Acute Respiratory Distress syndrome remains a significant cause of morbidity and 
mortality in critically ill patients.  Despite much investigation there has been no 
specific therapy shown to improve outcome and treatment remains supportive with the 
aim of minimising further lung damage by a protective ventilatory strategy. ARDS 
therefore remains a frustration to investigators, as despite a number of possible 
approaches to treating the disease, it seems that the complexity and overlap seen in the 
system prevents the identification of a single therapeutic intervention that 
dramatically alters the course of the illness. Indeed by the time the syndrome is 
clinically recognisable the over-exuberant immune response is underway and it would 
seem obvious that a single agent is unlikely to be able to target all the processes 
occurring. 
This therefore raises the possibility of trying to identify those at risk of ALI and 
treating them in order to attenuate any lung injury likely to develop. Those at risk of 
ALI are well recognised [12] and work in this institute has shown that early mediators 
can be identified that predict the development of ARDS [29]. Furthermore it would 
seem that these mediators are linked to early indicators of hypoxia [58] thus raising 
the possibility that hypoxic signalling contributes to the development of the organ 
injury. 
This thesis therefore aimed to study the role of a specific hypoxic signalling pathway, 




7.1 Development of a suitable model 
A significant part of the early work in this thesis was the development of a 
reproducible, robust in vivo model of lung injury.  A number of approaches were tried. 
The results are discussed in chapter 3. A model of reproducible injury was obtained 
by the instillation of endotoxin under direct visualisation. This model has a number of 
advantages: it generates a pattern of lung injury similar to that seen in humans; it has a 
similar time course with an early injury in response to the insult and resolution over 
time; by being done by direct visualisation of tracheal intubation the investigator can 
be confident that the insult has reached the tracheo-bronchial tree and that 
contamination of the instillate by oropharyngeal contents does not occur and finally 
by relying on the inhalation of the agent from the cannula by the animal the 
investigator can be confident that there is no barotrauma associated with the 
instillation of the insult. It is not known if this model reproduces the latter features of 
ARDS in humans as there was no histological evidence of fibrosis for example seen at 
any timepoint. It would be valuable to extend the timecourse of the model through to 
resolution of the injury. There are suggestions in the literature that the bleomycin 
model of pulmonary fibrosis is actually a good model of ARDS as it results in 
inflammatory cell damage and in some animals fibrosis [195]. The investigator is 
therefore faced with a choice. If they are interested in the early, neutrophil driven 
injury phase then endotoxin does represent a good model. However, if the area of 
interest focuses more on the resolution and reparative phases then other models may 
be of more interest. 
The lack of injury seen with the other approaches is puzzling as they are reported to 
cause injury in the hands of other investigators. This may reflect species differences 
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[65], strain differences [157;163;255;256] or other unrecognised technical 
considerations. 
 
7.2 MH-S data 
Macrophages are known to secrete inflammatory mediators in response to LPS. In this 
thesis the generation of one of these, nitric oxide has been studied in detail. It has 
been shown that there is a significant production of NO in response to LPS and that 
the production of NO can be manipulated, as would be expected, by manipulating the 
concentration of the key substrate, oxygen, in the culture conditions. Of clinical 
relevance it has been shown that in conditions of substrate limitation (i.e. hypoxic 
conditions) there is still generation of the key enzyme iNOS and that it is active and 
when there is restoration of substrate it is rapidly able to generate large quantities of 
NO. This raises the possibility that in critically injured patients the resuscitation 
process acts as a second hit generating increased amounts of NO both by the action of 
increased delivery of oxygen to macrophages as a result of increasing the inspired 
fraction of oxygen and also by increasing the delivery of primed macrophages in 
unventilated areas of lung by alveolar recruitment manoeuvres in ventilated patients. 
The presence of the three isoforms of NO Synthase in the MH-S cell line has been 
shown for the first time. This raises questions about the role of the lower output 
isoforms eNOS and nNOS in macrophages and is an area requiring further study. 
The ability of DMOG to augment the NO response to LPS but reduce the secretion of 
TNFα is also worthy of further work. Other investigators [217;219] have shown that 
in models of gut inflammation that DMOG attenuates the inflammatory damage seen. 
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The contrasting effects on NO and TNFα release by alveolar macrophages in response 
to DMOG raises the possibility that in the presence of live bacteria DMOG may be 
able to increase the killing of the bacteria by NO dependent mechanisms but avoid 
some of the unnecessary surrounding inflammatory damage generated by the release 
of TNFα.  This effect may be particularly useful in enclosed body cavities such as the 
pleural space where deleterious results of inflammation (loculated fluid collections 
and pleural thickening) can occur despite adequate antibiotic therapy (complicated 
parapneumonic effusion) [257]. If further work finds that DMOG alters the 
conversion of mTNFα to solTNFα then the therapeutic effect of this finding would be 
less clear. Increasing the mTNFα may actually result in increased local damage to 
tissues as a result of an increase in the local concentration of biologically active 
molecules [223]. Alternatively a situation could be envisaged where the inhibition of 
release of solTNFα results in a reduction in the systemic release of TNFα from the 
inflammatory nidus reducing the systemic effects of inflammation. Whatever the 
result this is an area of promise for future work. 
7.3 In vivo Data 
A key aim of this thesis was to test the role of myeloid cell Hif-1α in the development 
of Acute Lung injury in the animal model. Cramer et al [89] in their original report 
described dramatic reductions in the inflammatory response to stimuli in several 
models of tissue injury. However, in the data shown in this thesis there is less 
convincing evidence of a central role of Hif-1α in mediating injury in response to 
LPS. Other authors have shown that LPS increases Hif-1α in myeloid cells 
([142;208]. The data presented here shows that quantitatively, using standard 
measures of lung injury,  the reduction of myeloid cell Hif-1α in this animal line does 
not alter the pattern of acute injury following LPS instillation. In agreement with the 
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in vitro data there is a qualitative difference in the injury seen with evidence of 
reduced protein nitrosylation. It may be that the activation of other pathways, 
controlled by alternative transcription factors such as NF-κB, are still able to result in 
the activation of the inflammatory cascade. This possibility is supported by 
subsequent work from Professor Johnson’s laboratory [218] where in a model of soft 
tissue infection there was no difference in inflammatory infiltrate in wild type or Hif-
1α myeloid deplete animals. Alternatively there could be a dose effect and that at 
lower doses of LPS a difference in the inflammatory injury would have been seen. 
However as this thesis was interested in the clinical picture of ARDS it was felt 
appropriate to study the injury resulting from a significant insult. Time and animal 
constraints prevented a comparison of different doses of LPS at several different 
timepoints and it was felt that the initial study of high dose LPS over a clinically 
relevant timecourse was appropriate. Future work should involve following the 
resolution of the lung injury to see if the difference in BAL protein at 5 days persists 
and whether there are any clinically important differences in healing as a result of 
abnormal myeloid cell Hif-1α. Alterations in tissue repair are possible as Hif-1α is a 
key transcription factor controlling the release of CXCL-12 (also known as Stromal 
derived factor-1) which has been shown to be important in wound repair and 
progenitor cell trafficking [205;258]. The possibility of altered reparative processes 
also raises the possibility of altered disease in more chronic models of lung injury 






Hypoxia inducible factor-1 is a transcription factor that is central to the cellular 
response to hypoxia. More recent work has shown that it is also modulated by 
hormones and cytokines involved in the inflammatory response. It is also increased in 
response to bacterial cell wall products (LPS). Controlling the expression of over 70 
recognised gene products including a number of metabolic, inflammatory and 
angiogenic factors the role of Hif-1 in inflammatory injury has been the focus of 
recent interest.  
This thesis has sought to study the role of Hif-1α in inflammatory lung injury with a 
specific focus on the role of myeloid cell Hif-1α. Quantitatively there appears to be 
little difference in lung injury as a result of Hif-1α depletion. However in vivo and in 
vitro data suggest that there are qualitative differences which may be of significance 
in the pathophysiology of Acute Lung Injury. These data suggest that further 
important insights may be obtained by the continued study of the role of hypoxia 
inducible factor-1 (and its family members) in models of lung injury. 
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